Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 11928. Отображено 100.
14-09-2018 дата публикации

Устройство для долгосрочного хранения биообразца с ДНК

Номер: RU0000183227U1
Автор: Валентин Аркадьевич Лифшиц
Принадлежит: Валентин Аркадьевич Лифшиц

Устройство для долгосрочного хранения биологического образца с ДНК, содержащее ударопрочный герметичный контейнер со съемной крышкой, капсулу для размещения заключенного в твердую защитную оболочку сохраняемого образца ДНК, приспособленную для установки внутри контейнера, емкость для дезинфицирующего раствора, имеющую съемную крышку, на внутренней поверхности которой закреплена с возможностью отсоединения крышка по форме входного отверстия капсулы, с закрепленным на ее внутренней поверхности стержнем, несущим на своем конце держатель биологического образца. Входное отверстие капсулы в исходном состоянии герметизировано съемной защитной мембраной и в полости капсулы размещен консервирующий материал в вязкотекучем состоянии, в объеме, достаточном для полного погружения держателя с образцом ДНК, способный к формированию твердой защитной оболочки образца ДНК при нормальных условиях окружающей среды. 5 илл, 7 з.п. ф-лы. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 183 227 U1 (51) МПК C12M 3/00 (2006.01) C12N 5/071 (2010.01) A01N 1/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК C12M 3/00 (2006.01); C12N 5/00 (2006.01); A01N 1/00 (2006.01) (21)(22) Заявка: 2018113767, 16.04.2018 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Лифшиц Валентин Аркадьевич (RU) Дата регистрации: 14.09.2018 (56) Список документов, цитированных в отчете о поиске: RU 2228358 C2, 10.05.2004. RU 2346984 C2, 20.02.2009. RU 2639555 C2, 21.12.2017. RU 116475 U1, 27.05.2012. US 8900856 B2, 02.12.2014. (45) Опубликовано: 14.09.2018 Бюл. № 26 R U (54) Устройство для долгосрочного хранения биообразца с ДНК (57) Реферат: Устройство для долгосрочного хранения стержнем, несущим на своем конце держатель биологического образца с ДНК, содержащее биологического образца. Входное отверстие ударопрочный герметичный контейнер со капсулы в исходном состоянии герметизировано съемной крышкой, капсулу для размещения съемной ...

Подробнее
Номер записи: 1
03-05-2012 дата публикации

Systems and Methods for Tissue or Organ Removal

Номер: US20120109144A1
Автор: Albert K. Chin, Brian Deguzman, Lishan Aklog
Принадлежит: Pavilion Medical Innovations LLC

A system for tissue or organ removal is provided. The system has an outer bag having an exit end, and an inner bag situated within the outer bag and having an opening capable of receiving an organ or tissue. The inner bag may be sealed to the exit end of the outer bag about its opening. A fluid-tight space may be situated between the outer bag and the inner bag. The space may be designed to accommodate positive pressure which can act on the inner bag to cause the inner bag to evert and expel the organ or tissue. The system may also include an organ receiving component for receiving the organ as it is expelled. Methods for tissue or organ removal is also provided.

Подробнее
Номер записи: 2
28-06-2012 дата публикации

Container assembly and method for containing biological graft

Номер: US20120160714A1
Автор: Yusuke Nozaki
Принадлежит: Terumo Corp

A container assembly for containing a biological graft can include a housing member sized to be able to contain the biological graft while keeping the size of an original shape of the biological graft. An aqueous fluid can fill the housing member such that the biological graft is contained in a suspended state in the aqueous fluid.

Подробнее
Номер записи: 3
19-07-2012 дата публикации

Novel Composition for Treating External Injuries and Eschars

Номер: US20120183487A1
Автор: Denis Gilotin, Dominique Dissard, Henri Graugnard, Jean-Charles Jay, Laura Poli
Принадлежит: OGF

The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for external treatment of tissues of corpses.

Подробнее
Номер записи: 4
19-07-2012 дата публикации

Container and Supporting Structure for Housing an Organ

Номер: US20120184024A1
Автор: Anders Lindsten, Anna Beyer, Anna Soderlund, Audrius Paskevicius, Benjamin King, Joakim Nilsson, Maria Sperlingsson, Morgan Johansson, Peter Sebelius, Stig Steen
Принадлежит: VIVOLINE MEDICAL AB

An apparatus intended for evaluation, preservation and perfusion of an organ, such as a lung. The apparatus includes a container with a bottom portion, an insert portion and a lid portion. A pulmonary artery tube is intended to be connected to the lung pulmonary artery and a trachea tube is intended to be connected to the trachea of the lungs and bent tube connects the pulmonary artery tube to a circuit for providing a fluid to the pulmonary artery is provided. The circuit includes a pump, an oxygenator, an optional leukocyte-filter, and a holder for connecting the trachea tube to a source of respiration. There is an oxygenator tube set and a leukocyte-filter tube set. A supporting structure for the container comprises a recess sized for enclosing said container and a display panel. Moreover, there are two handles, which may be unfolded into a position for supporting a sterile cloth.

Подробнее
Номер записи: 5
02-08-2012 дата публикации

Method for treatment and storage of platelets

Номер: US20120196362A1
Автор: Ilya Y. Ilyin, James S. Jones, Maria E. Urusova, Maria G. Tkachman, Pavel Butylin, Rostislav Khorenyan, Semyon Kogan, William E. Grieshober
Принадлежит: Individual

Provides are improved methods for storing platelets and compositions that contain stored platelets for use in transfusions. The method entails obtaining a platelet concentrate from blood obtained from an individual and holding the platelet concentrate in at refrigerated temperatures under an atmosphere having a pressure of from 3.5 to 5 bars comprising more than 65% xenon and for at least one week. Also provided is a refrigerated composition that contains a platelet concentrate, wherein the platelet concentrate contains xenon, and wherein the platelet concentrate has been isolated from an individual for at least seven days.

Подробнее
Номер записи: 6
02-08-2012 дата публикации

Sperm Diluent Solution and Method for Artificial Insemination Using Same

Номер: US20120197068A1
Автор: Masayuki Shimada, Tetsuji Okazaki
Принадлежит: Individual

A sperm diluent of the present invention contains a chelating agent such as EDTA and/or, EGTA, which forms a complex with a calcium ion, in a base diluent. Further, the sperm diluent contains an immunosuppressive factor such as a steroid hormone and/or, a cytokine, which suppresses migration of leukocytes. By diluting frozen sperm with this sperm diluent followed by performing artificial insemination, death of the sperm before fertilization and phagocytosis of the sperm and embryos by leukocytes in the uterus can be suppressed, allowing enhancement of the conception rate and the implantation rate.

Подробнее
Номер записи: 7
23-08-2012 дата публикации

Production and use of high pressure for cryopreservation and cryofixation

Номер: US20120210734A1
Автор: Edmund René Troncoso, Gary A. Hoffman
Принадлежит: Individual

Methods and devices are described for the concurrent delivery of elevated pressures and low temperatures to a sample, typically but not exclusively a biological sample. A medium that expands on cooling and/or freezing is employed with a sample immersed therein, typically but not exclusively encased in a sample container. Cooling the medium lowers the temperature and applies pressure to the sample such that reduced damage to a typical biosample occurs. Relatively long-lived metastable phases are also produced, including both metastable liquids and solids, without the need for very rapid cooling steps as required in conventional achievement of such metastable phases. Preliminary test data are also presented.

Подробнее
Номер записи: 8
27-09-2012 дата публикации

Organ cold storage composition and methods of use

Номер: US20120244518A1
Автор: Lee Ann Macmillan-Crow
Принадлежит: University of Arkansas

The present invention provides compositions and methods for decreasing oxidative damage to an organ during cold storage.

Подробнее
Номер записи: 9
27-09-2012 дата публикации

Method of oocyte cryopreservation using antifreeze protein

Номер: US20120244616A1
Автор: Byung Chul Jee, Chang Suk Suh, Jun Woo Jo
Принадлежит: Bundang Hospital Seoul National University

Disclosed is a method for cryopreserving an oocyte by adding an antifreeze protein to a cryopreservation liquid (equilibrium solution, vitrification solution). The disclosed cryopreservation method of an oocyte minimizes damage to the oocyte, which increases the survival rate of the oocyte after freezing and thawing of the oocyte, and improves a fertilization rate, and a blastocyst development ratio of the oocyte.

Подробнее
Номер записи: 10
04-10-2012 дата публикации

Vitrification systems and methods

Номер: US20120251999A1
Автор: Emre Kayaalp, Sangjun Moon, Utkan Demirci, Xiaohui Zhang, Young Seok SONG
Принадлежит: Brigham and Womens Hospital Inc

The embodiments of the invention described herein relate to systems and methods for the vitrification of biological samples. Vitrification is achieved by generating nanodroplets of a solution comprising the biological sample with a means that can be automated and adapted to high-throughput applications.

Подробнее
Номер записи: 11
22-11-2012 дата публикации

Apparatus for oxygenation and perfusion of tissue for organ preservation

Номер: US20120292320A1
Автор: Jared Alden Judson, Lisa Maria MAIER
Принадлежит: Paragonix Technologies Inc

An apparatus to oxygenate and perfuse a bodily tissue for extracorporeal preservation of the bodily tissue. The apparatus may be used to transport donor organs for transplant. The apparatus includes a pneumatic system, a pumping chamber, and an organ chamber. The pneumatic system is configured for the controlled delivery of fluid to and from the pumping chamber based on a predetermined control scheme. The pumping chamber is configured to diffuse a gas into a perfusate and to generate a pulse wave for moving the perfusate through a bodily tissue. The pumping chamber is configured to substantially automatically purge excess fluid from the pumping chamber to an area external to the apparatus.

Подробнее
Номер записи: 12
06-12-2012 дата публикации

Methods and devices for preserving tissues

Номер: US20120309078A1
Автор: Jared Alden Judson, Lisa Maria Anderson
Принадлежит: Paragonix Technologies Inc

Methods and apparatus for preserving detached tissues, especially digits and limbs, which are detached as a result of traumatic amputation. By using the methods and apparatus, detached tissues can be preserved for greater lengths of time and are ultimately in a better condition for replantation surgery.

Подробнее
Номер записи: 13
10-01-2013 дата публикации

Modular sample store

Номер: US20130011226A1
Автор: Beat Reuteler, Christian Cachelin, Johann Camenisch, Jürg Tanner, Mirko Hebenstreit
Принадлежит: Brooks Automation Inc

A modular sample storeincluding a storage area; a service area; a transfer area; a motorized robot with a lifting device and at least one platform; and a controller. The sample store service area includes one integrally formed cubic vat module and the sample store storage area includes at least one integrally formed cubic vat module. Each one of the aforementioned vat modules includes an essentially horizontal vat floor and four joining vat walls that are connected to the vat floor and that are leaving an open vat space. The modular sample store also includes upper side walls and a cover plate to close the sample store. Each vat floor and vat wall includes an outside liner and an inside liner, which outside and inside liners in each case are separated by a clearance. This clearance is essentially filled with a polymer foam material that provides fixation of the outside and inside liners to each other as well as thermal insulation of and reinforcement to the thus integrally formed cubic vat module sandwich construction.

Подробнее
Номер записи: 14
10-01-2013 дата публикации

Organ care solution for ex-vivo machine perfusion of donor lungs

Номер: US20130011823A1
Автор: Anas Abdelazim, Ihab A. FATTAH, Paul Lezberg, Robert Havener, Tamer I. Khayal, Waleed H. Hassanein
Принадлежит: Individual

An ex-vivo lung solution for machine perfusion of donor lungs on OCS. The solution may be mixed with whole blood or packed red blood cells to form the OCS lung perfusion solution.

Подробнее
Номер записи: 15
14-02-2013 дата публикации

Biomaterial Freezing

Номер: US20130039382A1
Автор: Aaron Burke, Brian Pereira, Dennis Wong, Elias Noukas, Michael Felo
Принадлежит: EMD Millipore Corp

The biocontainer of the present invention provides a low cost, simple solution of many of the problems encountered during shipping, freezing and thawing of biopharmaceutical materials. The present invention enables a user to monitor the temperature profile of each biopharmaceutical container during the cryogenic process, so as to ensure the integrity of materials within each biocontainer by using a pre-installed and pre-sterilized temperature sensor. In some embodiments, the sensor assembly includes a wireless transmitter and is capable of transmitting information regarding the measured reading. In other embodiments, the sensor assembly includes a processing unit, which determines whether the temperature profile is acceptable. In a further embodiment, an indicator is included, such that the processing unit may indicate whether the biopharmaceutical material has been properly frozen. In other embodiments, the sensor assembly also includes a storage element, which is capable of storing various parameters during the freezing process.

Подробнее
Номер записи: 16
07-03-2013 дата публикации

Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells

Номер: US20130059286A1
Автор: Hsiu-Kang Chang, Wei-Yu Lo
Принадлежит: HealthBanks Biotech Co Ltd

A method of preserving an umbilical cord is disclosed. The method comprises obtaining a segment of an umbilical cord; mincing the segment of the umbilical cord into cord tissue pieces; admixing the cord tissue pieces with a cryogenic composition comprising a cryoprotectant and a protein to form a mixture; shaking the mixture for a duration of no shorter than 20 minutes and no longer than 40 minutes; and cryopreserving the mixture.

Подробнее
Номер записи: 17
07-03-2013 дата публикации

Solution for non-programmed cell cryopreservation

Номер: US20130059381A1
Автор: Baoli Wei, Dunwu Zheng, Jiahui Chen, Qingyan Luo, Xiaoying Mo
Принадлежит: CYAGEN BIOSCIENCES (GUANGZHOU) Inc

The invention provides a solution for non-programmed cell cryopreservation, which comprises 1.0-28 w/v % of cell membrane protectant, 1.0-18 w/v % of permeable intracellular protectant, 3.0-28 w/v % of cell sedimentation stabilizer, and the balance of solvent. The cell cryopreservation solution provided by the invention is good for protecting cells. After the cryopreservation solution is added to cells, the cells can be cryopreserved in a refrigerator of −80 DEG C. directly without complicated programmed cryopreservation, thus, the time for cell cryopreservation is shortened greatly and the efficiency of cryopreservation is improved. Therefore, the cryopreservation solution is suitable for cryopreserving a large number of cells. The recovery rate of the cells cryopreserved is high, the growth and differentiation of the recovered cells is normal. The components of the cryopreservation solution are stable, thus the cryopreservation solution can be preserved with good property for a long time.

Подробнее
Номер записи: 18
18-04-2013 дата публикации

Method for preserving a whole mammalian organ

Номер: US20130095467A1
Автор: Doubleday Marc
Принадлежит: OPK BIOTECH, LLC.

Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes. 1. A method of preserving a whole mammalian organ , comprising contacting the whole organ with a solution comprising (a) polymerized hemoglobin derived from mammalian blood and (b) cell culture medium.2. A method according to claim 1 , where the organ is a human liver claim 1 , a human lung claim 1 , or a human kidney. This application is a divisional of U.S. application Ser. No. 13/041, 685, filed Mar. 7, 2011, which is a continuation of U.S. application Ser. No. 11/626,727, filed Jan. 24, 2007, which claims the benefit of U.S. Provisional Application No. 60/761,663, filed on Jan. 24, 2006.The entire teachings of the above applications are incorporated herein by reference.The application relates to the field of cell biology. In particular, the application relates to solutions, suspensions, methods, and processes useful for the isolation, culture, and transplantation of cells and tissues.The transplantation of cells, tissues, and organs holds great promise for the treatment of many diseases. For example, pancreatic islet transplantation can reverse insulin-dependent diabetes. Unfortunately, the procedure is hampered by a short supply of islets and a gradual loss of islet function after transplantation. The inconsistency of islet isolation outcomes has been a major limitation to widespread clinical application of islet ...

Подробнее
Номер записи: 19
23-05-2013 дата публикации

COMPOSITION FOR THE COLD STORAGE OF ORGANS

Номер: US20130130225A1
Автор: C.Y. Chang Haisul, Fernández Gallego Victor, Iñiguez Martínez María, Lopez Novoa Jose Miguel, Prieto Valtuena Jesus Maria, Ruiz Echeverría Juan
Принадлежит:

The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods. 1. Cold organ preservation composition that comprises , jointly or separately ,(i) cardiotrophin-1 or a functionally equivalent variant thereof and(ii) a cold organ preservation solution.2. The composition according to claim 1 , wherein the cold organ preservation solution comprises(a) at least one buffer agent(b) at least one impermeating agent and(c) at least one electrolyte.3. The composition according to claim 2 , wherein the buffer agent is selected from the group consisting of phosphate claim 2 , bicarbonate claim 2 , sulfate claim 2 , histidine claim 2 , histidine-HCl claim 2 , HEPES claim 2 , citrate and a combination thereof; the impermeating agent is selected from the group formed by histidine claim 2 , glucose claim 2 , sucrose claim 2 , mannitol claim 2 , trehalose claim 2 , gluconate claim 2 , citrate claim 2 , lactobionate claim 2 , raffinose and a combination thereof; and/or the electrolyte is selected from the group formed by sodium claim 2 , potassium claim 2 , magnesium claim 2 , calcium claim 2 , chloride and a combination thereof.4. (canceled)5. The composition according to claim 1 , wherein the cold organ preservation solution additionally comprises at least one colloid agent claim 1 , at least one metabolic agent claim 1 , at least one amino acid claim 1 , at least one antioxidant agent claim 1 , at least one vitamin and/or at least one antibiotic.6. (canceled)7. The composition according to claim 5 , wherein the colloid agent is selected ...

Подробнее
Номер записи: 20
30-05-2013 дата публикации

Method of cryopreserving selected sperm cells

Номер: US20130137081A1
Автор: John L. Schenk
Принадлежит: XY LLC

The present invention provides a method of cryopreserving sperm that have been selected for a specific characteristic. In a preferred embodiment, the method is employed to freeze sex-selected sperm. Although the cryopreservation method of the invention can be used to freeze sperm selected by any number of selection methods, selection using flow cytometry is preferred. The present invention also provides a frozen sperm sample that has been selected for a particular characteristic, such as sex-type. In preferred embodiments, the frozen sperm sample includes mammalian sperm, such as, for example, human, bovine, equine, porcine, ovine, elk, or bison sperm. The frozen selected sperm sample can be used in a variety of applications. In particular, the sample can be thawed and used for fertilization. Accordingly, the invention also includes a method of using the frozen selected sperm sample for artificial insemination or in vitro fertilization.

Подробнее
Номер записи: 21
30-05-2013 дата публикации

One-Step Cell and Tissue Preservative for Morphologic and Molecular Analysis

Номер: US20130137094A1
Автор: Claudius Mueller, Lance A. Liotta, Virginia A. Espina
Принадлежит: George Mason Intellectual Properties Inc

The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer. In still another embodiment, the compositions further include lactic acid at a concentration sufficient to maintain cellular nuclear volume at a level equivalent to aldehyde fixation of the same type of cell. In a further embodiment, the composition comprises: a) a precipitating fixative, b) a reversible/cleavable cross-linker, c) a permeation enhancer, d) a kinase inhibitor, e) a phosphatase inhibitor, and f) a carboxylic acid. In a still further embodiment, the invention comprises method for preserving a biological sample by contacting the sample with the composition of the invention under conditions effective for the preservation of the sample.

Подробнее
Номер записи: 22
06-06-2013 дата публикации

TRANSPLANTS

Номер: US20130143833A1
Автор: Dobson Geoffrey Phillip
Принадлежит: Hibernation Therapeutics Limited

The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. 17-. (canceled)8. A method of reducing injury to vasculature that has been explanted or implanted by administering to the vasculature ex vivo a composition including:(i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and(ii) an antiarrhythmic agent.9. A method according to claim 10 , wherein the composition further includes at least one muscle relaxant.10. A method according to claim 11 , wherein the muscle relaxant is selected from the group consisting of a botulinum toxin claim 11 , myosin light chain kinase inhibitor claim 11 , calmodulin blocker claim 11 , calcium channel blocker claim 11 , nitric oxide donor claim 11 , dipyridamole claim 11 , beta blocker claim 11 , Na/H inhibitor claim 11 , high magnesium claim 11 , opioid claim 11 , phosphodiesterase inhibitors claim 11 , alpha-adrenergic receptor antagonists and Rho kinase inhibitors.11. A method according to claim 12 , wherein the phosphodiesterase inhibitor is selected from the group consisting of papaverine claim 12 , milrinone claim 12 , theophylline and dipyridamole.12. A method according to claim 12 , wherein the alpha-adrenergic receptor antagonist is phenoxybenzamine.13. A method according to claim 12 , wherein the Rho kinase inhibitor is selected from the group consisting of HA1077 and fausdil.14. A method according to claim 10 , wherein the composition is pre-mixed with the patient's blood.15. A method according to claim 10 , wherein ...

Подробнее
Номер записи: 23
13-06-2013 дата публикации

Methods for sorting particles

Номер: US20130149736A1
Автор: Gary Durack, Gary P. Vandre, Jeffrey D. Wallace, Jeremy T. Hatcher, Lon A. Westfall, Niraj Nayak
Принадлежит: INGURAN LLC

A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.

Подробнее
Номер записи: 24
27-06-2013 дата публикации

PLATFORM FOR ENGINEERED IMPLANTABLE TISSUES AND ORGANS AND METHODS OF MAKING THE SAME

Номер: US20130164339A1
Автор: Dorfman Scott, Khatiwala Chirag, Murphy Keith, Presnell Sharon, Shepherd Benjamin
Принадлежит: ORGANOVO, INC.

Disclosed are engineered tissues and organs comprising one or more muscle cell-containing layers, the engineered tissue or organ consisting essentially of cellular material, provided that the engineered tissue or organ is implantable in a vertebrate subject and not a vascular tube. 1. A living , three-dimensional engineered tissue or organ comprising one or more layers , the one or more layers characterized by one or more of: a) substantially scaffold-free at the time of use; and b) bioprinted , the one or more layers suitable for implantation in a vertebrate subject upon sufficient maturation; provided that at least one layer of the engineered tissue or organ comprises muscle cells and that the engineered tissue or organ is not a vascular tube.2. The tissue or organ of claim 1 , wherein at least one layer comprises a plurality of cell types claim 1 , the cell types spatially arranged relative to each other to create a planar geometry.3. The tissue or organ of claim 2 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.4. The tissue or organ of claim 1 , comprising a plurality of layers claim 1 , at least one layer compositionally or architecturally distinct from at least one other layer to create a laminar geometry.5. The tissue or organ of claim 4 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.6. The tissue or organ of claim 1 , wherein the tissue or organ is a sac claim 1 , sheet claim 1 , or tube claim 1 , wherein said tube is not a vascular tube.7. The tissue or organ of claim 1 , wherein the tissue or organ is substantially free of any pre-formed scaffold at the time of use.8. The tissue or organ of claim 1 , wherein the tissue or organ is bioprinted.9. The tissue or organ of claim 1 , wherein the one or more layers generates an extracellular matrix.10. The tissue or organ of claim 1 , wherein the muscle cells are smooth muscle cells.11. The ...

Подробнее
Номер записи: 25
27-06-2013 дата публикации

INORGANIC PYROPHOSPHATE AND USES THEREOF

Номер: US20130164732A1
Автор: Sutovsky Peter, Yi Young-Joo
Принадлежит: The Curators of the University of Missouri

The present invention provides a new and improved sperm stimulating additive comprising a certain amount of inorganic pyrophosphate (PPi). Addition of PPi in the media for human/animal in vitro fertilization (IVF) improves fertilization rate; addition of PPi in the semen extender for farm animal artificial insemination (AI) may improve pregnancy rates; furthermore, mammalian oocytes matured in vitro in a medium including PPi attain improved fertilization and developmental potential, while embryos cultured in medium supplemented with PPi have improved development to blastocyst. 1. A sperm preservation media comprising inorganic pyrophosphate (PPi).2. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 200 μM.3. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 20 μM.4. The sperm preservation media of claim 1 , wherein the concentration of PPi is about 10 μM.5. The sperm preservation media of claim 1 , wherein said preservation media is used to preserve sperm from a porcine.6. A media for sperm processing comprising inorganic pyrophosphate (PPi).7. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 200 μM.8. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 20 μM.9. A media for in vitro fertilization (IVF) or artificial insemination (AI) comprising inorganic pyrophosphate (PPi).10. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 200 μM.11. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 20 μM.12. A semen sexing method claim 9 , comprising:(a) separating a mixed sperm suspension in a first culture medium into a population of x-bearing or y-bearing sperm with the aid of an elutant medium;(b) preserving the x-bearing or y-bearing sperm in a second culture medium,wherein, inorganic pyrophosphate (PPi) is added ...

Подробнее
Номер записи: 26
04-07-2013 дата публикации

Flush preservation solution

Номер: US20130171613A1
Автор: Lodge Jeremy Peter Alan, Potts David
Принадлежит:

Flush preservation solution for the preservation of cells in the absence of a blood supply comprising: 149.-. (canceled)51. The flush preservation solution of claim 50 , comprising:iv) at least one component with calcium transport blocking properties and optionally additionally a component with an anti-calcium action activity.52. The flush preservation solution of claim 50 , wherein the calcium transport blocker is selected from the group consisting of nicardipine claim 50 , diltiazem claim 50 , verapamil claim 50 , nisoldipine claim 50 , chlorpromazine and trifluorperazine.53. The flush preservation solution of claim 50 , wherein the pH buffer is selected from the group consisting of a sodium phosphate buffer claim 50 , a potassium phosphate buffer claim 50 , and combinations thereof.54. The flush preservation solution of claim 50 , which additionally comprises:xiv) at least one component that acts reversibly upon crossbridge function in muscle.55. Flush preservation solution for heart preservation which comprises a combination of component classes given below of specific type listed{'sub': 2', '4, 'iii) NaHPO'}{'sub': 2', '4', '2, 'iii) NaHPO.2HO'}{'sub': 2', '4, 'iii) KHPO'}ii) Sucrose{'sub': '2', 'viii) MgCl'}{'sub': '2', 'viii) CaCl'}viii) NaCliv) Diltiazem57. A method for the preparation of a flush preservation solution as claimed in claim 50 , comprising adding components under pharmaceutically acceptable conditions in sequence to water claim 50 , and unstable components if any claim 50 , and dissolving claim 50 , adding any unstable components and making the solution nearly up to volume and finally making up to volume to regulate pH claim 50 , sterilising and cooling.58. The flush preservation solution of claim 50 , wherein said component with an anti-calcium action activity comprises a calcium chelator.59. The flush preservation solution of wherein component (ii) is present in an amount in the range 50-150 mmol/l claim 50 , each component (iii) is present ...

Подробнее
Номер записи: 27
18-07-2013 дата публикации

Compositions and methods for modulating ischemic injury

Номер: US20130183654A1
Автор: Banas Richard A., Rupp Randall G., Steed David L.
Принадлежит: STEMNION, INC.

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising Inflammatory Response Modulating Cells (IRMCs) , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.2. A method for reducing ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.3. A method for increasing the time to ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.43. The method of any one of , , or wherein the IRMCs are selected from the group consisting of extraembryonic (EE) cells , extraembryonic HLA-G positive (EHP cells) , Amnion-derived Multipotent Progenitor (AMP) cells , Mesenchymal Stem Cells (MSC) , Sertoli cells , hepatic stellate cells , adult basal fibroblasts , donor matched unseparated bone marrow cells , donor ...

Подробнее
Номер записи: 28
18-07-2013 дата публикации

COAGULATION CONTROLLING AGENTS AND DEVICES COMPRISING THE SAME

Номер: US20130183655A1
Автор: Dudaronek Justyna, Hoke Randal Alan, Holmes Paul F., Monroe Dougald, Novarra Shabazz
Принадлежит: BECTON, DICKINSON AND COMPANY

A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample. 1. A container for collecting serum , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving the blood , wherein said reservoir comprises thrombin and at least one coagulation controlling agent , and a closure.2. The container of claim 1 , wherein said coagulation controlling agent is a polycarboxylic acid compound having a molecular weight of less than about 500 g/mol.3. The container of claim 2 , wherein said polycarboxylic acid compound is selected from the group consisting of citrate or isocitrate.4. The container of claim 2 , wherein a concentration of said coagulation controlling agent ranges from about 0.5 mM to about 100 mM of concentrated formulation.5. The container of claim 4 , wherein a concentration of said coagulation controlling agent ranges from about 1 mM to about 50 mM of concentrated formulation.6. The container of claim 1 , wherein said coagulation controlling agent is a protamine salt or a homolog or derivative thereof.7. The container of claim 6 , wherein a concentration of said coagulation controlling agent ranges from about 0.05 mg/mL to about 5 mg/mL of blood sample.8. The container of claim 7 , wherein a concentration of said coagulation controlling agent ranges from about 0.25 mg/mL to about 0.5 mg/mL of blood sample.9. The container of claim 1 , wherein said coagulation controlling agent is a weak competitive inhibitor of thrombin ...

Подробнее
Номер записи: 29
18-07-2013 дата публикации

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

Номер: US20130183656A1
Автор: Lenz Richard, Moreno Juan, Vishwanath Ramakrishnan
Принадлежит: INGURAN, LLC

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1. A method of treating sperm cells during processing to improve cell integrity comprising the steps of:a. providing a sperm cell sample;b. processing the sperm cell sample; andc. adding one or more OSRs in the concentration range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample to form a sperm cell composition.2. The method as claimed in claim 1 , further comprising the step of holding the sperm cell composition at a holding temperature without freezing for a period of time in the range of about 2 seconds to about a week following addition of the one or more OSRs.3. The method as claimed in claim 2 , wherein the holding period is selected from a range selected from the group of: about 2 sec to about 3 min; about 3 min to about 15 min; about 15 min to about 1 hr; about 1 hr to about 8 hrs; about 8 hrs to about 12 hrs; about 12 hrs to about 18 hrs; about 8 hrs to about 24 hrs; about 24 hrs to about 48 hrs; about 48 hrs to about 72 hrs;about 72 hrs to about 96 hrs; about 96 hrs to about 120 hrs; about 120 hrs to about 144 hrs; ...

Подробнее
Номер записи: 30
25-07-2013 дата публикации

SPERM CRYOPROTECTIVE MEDIA

Номер: US20130189669A1
Автор: Farley Jane S., Ostermeier G. Charles, Taft Robert, Wiles Michael V.
Принадлежит: THE JACKSON LABORATORY

Described herein are methods for sperm cryoprotection and compositions comprising a cryoprotectant; a membrane protectant that stabilizes or assists in stabilization of membranes of sperm; and a free radical scavenger (e.g., a reducing agent, an antioxidant). 1. A method for cryogenically preserving rodent sperm , comprising adding to the sperm , prior to cryopreservation , a composition that comprises at least one cryoprotectant; at least one membrane protectant; and reduced glutathione , beta-mercaptoethanol or a combination thereof.2. The method of claim 1 , wherein the cryoprotectant is selected from the group consisting of raffinose claim 1 , lactose claim 1 , trehalose claim 1 , melibiose claim 1 , melezitose claim 1 , mannotriose claim 1 , stachyose claim 1 , dextran claim 1 , sucrose claim 1 , and sugar alcohols thereof claim 1 , glycerol claim 1 , maltitol claim 1 , and lactitol.3. The method of claim 1 , wherein the cryoprotectant is raffinose or lactose.4. The method of claim 1 , wherein the membrane protectant is a protein selected from the group consisting of egg protein claim 1 , egg yolk protein claim 1 , egg white protein claim 1 , casein claim 1 , albumin claim 1 , keratin claim 1 , collagen claim 1 , atelocollagen claim 1 , elastin claim 1 , gelatin claim 1 , peptones claim 1 , fibrinogen claim 1 , fibronectin claim 1 , a soy protein claim 1 , a wheat protein claim 1 , a corn protein claim 1 , a milk protein claim 1 , and hydrolysates thereof.5. The method of claim 1 , wherein the membrane protectant is skim milk or a component thereof milk powder or a component thereof; or egg yolk or a component thereof.6. The method of claim 1 , wherein the rodent sperm is isolated from a mouse.7. The method of claim 6 , wherein the mouse is an inbred mouse strain or substrain.8. The method of claim 1 , wherein the rodent sperm is isolated from a rat.9. The method of claim 1 , wherein the cryoprotectant is raffinose claim 1 , lactose claim 1 , or glycerol; the ...

Подробнее
Номер записи: 31
25-07-2013 дата публикации

Method for Improving Vein Performance in Bypass Surgery

Номер: US20130190270A1
Автор: Hans W. J. Niessen
Принадлежит: Individual

Methods to reduce damage to organelles, cells, tissues, organs and organ systems or components thereof caused by strain due to mechanical stress, including stretch stress and shear stress, are provided. The methods involve treating the organelles, cells, tissues, organs, and organs systems or components thereof (such as veins used for grafts in bypass surgery) with PX-18 and related compounds. Treatment with PX-18 and related compounds reduces damage due to stress and improves the functioning of the cells, tissues, organs or organs systems or components thereof. For example, the methods prevent the buildup of atherosclerotic plaque in transplanted (grafted) veins after coronary bypass surgery.

Подробнее
Номер записи: 32
08-08-2013 дата публикации

PERFUSION SOLUTION

Номер: US20130203041A1
Автор: Franklin ROSENFELDT, Marlin ALFORD, Robert DOWBEN
Принадлежит: ORGAN PERFUSION PTY LIMITED

The invention provides a perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na; a source of 10 to 20 mM K; a source of 5 to 10 mM Mg; a source of 0.25 to 0.75 mM Ca; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,/N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N/-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO; 1 to 30 mM glucose; 1 to 20 U/L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and optionally a diluent. The invention also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition. 1. A perfusion stock composition , for preserving a donor organ for transplantation , comprising:{'sup': '+', '(a) a source of 60 to 100 mM Na;'}{'sup': '+', '(b) a source of 10 to 20 mM K;'}{'sup': '2+', '(c) a source of 5 to 10 mM Mg;'}{'sup': '2+', '(d) a source of 0.25 to 0.75 mM Ca;'}(e) 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES);{'sub': '3', 'sup': '−', '(f) a source of 10 to 30 mM HCO;'}(g) 1 to 30 mM glucose;(h) 1 to 20 U/L insulin;(i) 1 to 10 mM fructose diphosphate or a salt thereof;(j) 1 to 40 mM aspartate or glutamate;(k) 1 to 10 mM adenosine, cAMP or cGMP;(l) 1 to 10 mM reduced glutathione; and(m) 30 to 100 mM lactobionate or mannitol; and optionally(n) a ...

Подробнее
Номер записи: 33
08-08-2013 дата публикации

METHODS AND SYSTEMS FOR PROCESSING BIOLOGICAL FLUIDS

Номер: US20130203042A1
Автор: Min Kyungyoon, Radwanski Katherine
Принадлежит: Fenwal, Inc.

Methods and container systems for processing biological fluids are disclosed. The container systems include an inner container within an outer container. The inner container wall is made of a porous material of a selected porosity that allows certain components to pass through said porous wall but retains other components. A treating solution is introduced into the chamber of the outer container. 1. A container system for the treatment of a biological fluid comprising:a) an outer container including an interior chamber;b) an inner container suspended within said interior chamber of said outer container, said inner container comprising at least one wall defining an interior chamber of said inner container, wherein said wall is made of a porous material selected to allow passage of only certain components of said biological fluid across said wall;c) a port communicating with said interior chamber of said outer container; andd) at least one port communicating with said inner container.2. The container system of wherein said inner and outer containers are made a flexible polymeric material.3. The container system of wherein at least said outer container is made of rigid polymeric material.4. The container system of wherein said outer container includes a sealed peripheral edge and said inner container includes a peripheral edge captured within said outer container peripheral sealed edge.5. The container system of wherein said inner container is suspended within said interior chamber of said outer container.6. The container system of comprising a flow path that communicates with at least said one port and said inner chamber of said inner container.7. The container system of Claim wherein said inner container has a surface area of approximately 150-400 cmand said outer container has a surface area of approximately 250-600 cm.8. The container system of further comprising a sample pouch in flow communication with one of said interior chamber of said inner container and said ...

Подробнее
Номер записи: 34
15-08-2013 дата публикации

ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS

Номер: US20130209425A1
Автор: Agulnick Alan, Baetge Emmanuel E., Green Chad, Kelly Olivia, Kroon Evert, Martinson Laura
Принадлежит: VIACYTE, INC.

The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. 111-. (canceled)12. A method for cryopreserving an in vitro cell population comprising:a. obtaining cells to be cryopreserved;b. incubating the cells to be cryopreserved in a freezing medium comprising dimethyl sulfoxide solution (DMSO) for longer than 5 minutes; andc. decreasing the temperature of the cells to be cryopreserved to less than 0° C. following incubation in DMSO.13. The method of wherein the cells to be cryopreserved are human pancreatic progenitor cells.14. The method of wherein the cells to be cryopreserved are human pancreatic progenitor cell aggregates.15. The method of wherein the freezing medium further comprises compounds selected from the group comprising Dulbecco's Modified Eagle's Medium (DMEM) claim 12 , Xeno-free Knockout Serum Replacement claim 12 , (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) (HEPES) and combinations thereof.16. The method of wherein the freezing medium further comprises DMEM with 30% Xeno-free Knockout Serum Replacement claim 14 , 25 mM HEPES and 10% DMSO solution.17. The method of wherein the cells to be cryopreserved are incubated in the freezing media for about 60 minutes.18. The method of wherein the cells to be cryopreserved are incubated in the freezing media for about 15 minutes at ambient temperature and then 45 minutes at 4° C.19. The method of claim 12 , wherein the cells to be cryopreserved are loaded into an implantable semi-permeable device prior to step b.20. The method of wherein the temperature of the cells to be cryopreserved in step c is decreased to at least −20° C.21. The method of wherein the temperature of the cells to be cryopreserved in step c is decreased to at least −90° C.22. The method of wherein the temperature of the cells to be ...

Подробнее
Номер записи: 35
15-08-2013 дата публикации

SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS

Номер: US20130209985A1
Автор: Dudaronek Justyna M., Hoke Randal A., Moskowitz Keith A., Sinquett Frank
Принадлежит:

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided. 1. A device for collecting and stabilizing blood or plasma , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving whole blood or plasma , and which comprises an anticoagulant , an antiplatelet agent comprising a prostaglandin , a phosphodiesterase inhibitor , a cyclooxygenase inhibitor , or a combination or two or more thereof , and a solubilization agent , wherein the anticoagulant and the antiplatelet agent are each present in an amount to stabilize the blood or plasma.2. The device of claim 1 , wherein the anticoagulant is selected from the group consisting of EDTA or a salt thereof claim 1 , oxalates claim 1 , citrate claim 1 , heparin claim 1 , a combination of citrate claim 1 , theophylline claim 1 , adenosine and dipyridamole (CTAD) claim 1 , sodium polyanethol sulfonate claim 1 , acid citrate dextrose claim 1 , and combinations of two or more thereof.3. The device of claim 1 , wherein the anticoagulant is present in a concentration of about 1 mM to about 200 mM claim 1 , relative to volume of the blood or plasma collected into the device.4. The device of claim 1 , wherein the antiplatelet agent is a prostaglandin.5. The device of claim 4 , wherein the prostaglandin comprises prostaglandin E1 claim 4 , prostaglandin E2 or a combination thereof.6. The device of claim 1 , wherein the prostacyclin comprises carbaprostacyclin claim 1 , beraprost claim 1 , iloprost claim 1 , 5 claim 1 ,6-dihydroprostacyclin claim 1 , ciprostene claim 1 , limaprost claim 1 , 13 claim 1 ,14-dehydro-15-cyclohexyl carbaprostacyclin claim 1 , taprostene claim 1 , and or a combination of two or more thereof.7. The ...

Подробнее
Номер записи: 36
15-08-2013 дата публикации

Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures

Номер: US20130209997A1
Автор: Rolf Müller, Scott E. Whitney, Senait Ghirmai
Принадлежит: Biomatrica Inc

Compositions and methods are disclosed for substantially liquid, gel, suspension, slurry, semisolid and/or colloid storage of biological samples following admixture with the herein disclosed storage composition, permitting substantial recovery of biological activity following storage without refrigeration. In certain embodiments, unfractionated saliva samples may be stored without refrigeration for weeks, months or years in a form that permits recovery of intact DNA following the storage period.

Подробнее
Номер записи: 37
22-08-2013 дата публикации

Method for dental pulp cryopreservation

Номер: US20130217123A1
Автор: Elisa Giovanna Angela Montelatici, Ferruccio Bonino, Gabriella Andriolo, Lorenza Lazzari, Paolo Rebulla, Silvia Gioventù, Stefania Frasca
Принадлежит: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

The present invention relates to a method for cryopreserving the pulp of a non-exfoliated deciduous tooth, comprising a step of making with a laser a hole into the tooth removed from its physiological seat on the tooth neck. After making the hole, the tooth is contacted with a cryopreserving agent and then cryofrozen. An object of the invention further consists in mesenchymal stem cells isolated from the pulp of a cryopreserved tooth according to the method of the invention.

Подробнее
Номер записи: 38
29-08-2013 дата публикации

Sperm processing methods

Номер: US20130224734A1
Автор: Gary Durack, Gary P. Vandre, Jeffrey D. Wallace, Jeremy T. Hatcher, Lon A. Westfall, Niraj V. Nayak
Принадлежит: INGURAN LLC

A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.

Подробнее
Номер записи: 39
26-09-2013 дата публикации

Tissue Preservation Fluid

Номер: US20130251663A1
Автор: Berry Stephen D., Martens Robert
Принадлежит: GREENBLENDZ, INC.

An improved non-formaldehyde-based preservative fluid is provided, comprising deionized water, a food-grade preservative, selected from the group consisting of sodium erythorbate and stereoisomers of ascorbic acid; and a humectant, selected from the group consisting of glycerin, glycerol, propylene glycol, glyceryl triacetate, and similar hygroscopic materials. Optional lanolin, dyes, or fragrances may be added as desired. Use of the improved fluid results in a more life-like appearance of the body, better tissue preservation, low odor, and a safer and environmentally sound alternative to conventional preservation fluids. 1. An improved tissue preservative fluid , comprising:(a) deionized water in an amount of 5% to 95%;(b) a food-grade preservative, selected from the group consisting of sodium erythorbate and stereoisomers of ascorbic acid, in an amount of 0.5% to 10%; and(c) a humectant, selected from the group consisting of glycerin, glycerol, propylene glycol, glyceryl triacetate, and similar hygroscopic materials, in an amount of 5% to 75%.2. The fluid of claim 1 , further including a lanolin material in an amount of 0.01% to 1%.3. The fluid of claim 1 , further including a dye in an amount of 0.1% to 2%.4. The fluid of claim 1 , further including a fragrance in an amount of 0.1% to 2%.5. A method for preserving a body claim 1 , comprising the steps of draining blood from the circulatory system of the body; and injecting a preservative fluid into the circulatory system of the body claim 1 , the preservative fluid comprising:(a) deionized water in an amount of 5% to 95%;(b) a food-grade preservative, selected from the group consisting of sodium erythorbate and stereoisomers of ascorbic acid, in an amount of 0.5% to 10%; and(c) a humectant, selected from the group consisting of glycerin, glycerol, propylene glycol, glyceryl triacetate, and similar hygroscopic materials, in an amount of 5% to 75%.6. The method of claim 5 , wherein the preservative fluid further ...

Подробнее
Номер записи: 40
26-09-2013 дата публикации

Tissue retrieval, storage, and explant culture device for the derivation of stem cells

Номер: US20130252226A1
Автор: Russell James Schweizer
Принадлежит: Individual

A device is provided for securing a tissue sample from biological material. The tissue sample is housed in bottom and top platens that are configured to promote fluid communication between the tissue sample and the exterior environment to permit transport or cryogenic fluid to contact the sample. Additionally, diskette assemblies may be provided within the platens that permit sub-samples to be separated without directly handling the tissue sample. The diskette assemblies may also be configured to promote fluid communication with the sub-sample housed therein.

Подробнее
Номер записи: 41
26-09-2013 дата публикации

Cryoembedded cell concentrates, methods for making, and methods for using

Номер: US20130252240A1
Автор: Anne Cutler, Eileen Margaritov, Janet Liddell, Olivia Herman, Ryan Noreen, Scott Cockayne, Scott Gill, Suneeti Mané
Принадлежит: Ventana Medical Systems Inc

Methods for preparing a cryoembedded cell concentrate are disclosed. The cryoembedded cell concentrate can be sectioned for use in methods (e.g., immunohistochemistry assays, immunocytochemistry assays, methods that use light or fluorescent microscopy, in situ hybridization assays, or diagnostic methods). Also disclosed are kits comprising cryoembedded cell concentrates.

Подробнее
Номер записи: 42
03-10-2013 дата публикации

HEPARAIN-BULKING AGENT COMPOSITIONS AND METHODS THEREOF

Номер: US20130260363A1
Автор: Farrar Quinton, Schalhoub Kenneth G., Tyler Joseph E.
Принадлежит: SMITHS MEDICAL ASD, INC.

A free-flowing anti-coagulant powder composition, the anti-coagulant composition containing heparin and a bulking agent that is lyophilized or spray dried and ground into a powder. The powdered anti-coagulant composition can be dry filled into syringes and other blood collections systems for rapid dissolution and mixing with collected blood sample without agitation of the container. The formulation may also retain a portion of the initial moisture, which may improve the shelf life and stability of the composition. 1. A method of preparing a heparin-bulking agent composition , the method comprising:providing a heparin component and at least one bulking agent;dissolving the heparin component and the at least one bulking agent in a solution to form a heparin-bulking agent formulation;drying the heparin-bulking agent formulation to form a heparin-bulking agent composition having a solid mass; andgrinding the solid mass of the heparin-bulking agent composition to a particulate size such that the heparin-bulking agent composition comprises a free-flowing powder.2. The method of claim 1 , wherein the heparin component is a heparin salt chosen from lithium claim 1 , sodium claim 1 , calcium claim 1 , zinc or combinations thereof.3. The method of claim 2 , wherein the heparin component is provided as a solution claim 2 , an aqueous solution claim 2 , a solid material claim 2 , or a lyophilized heparin salt.4. The method of claim 2 , wherein the bulking agent is a water soluble material chosen from a sugar alcohol claim 2 , a carbohydrate claim 2 , a water-soluble polymer claim 2 , or combinations thereof.5. The method of claim 4 , wherein the water soluble material is chosen from mannitol claim 4 , trehalose claim 4 , raffinose claim 4 , sorbitol claim 4 , sucrose claim 4 , lactose claim 4 , polyvinylpyrollidone claim 4 , and combinations thereof.6. The method of claim 5 , wherein the water soluble bulking agent is provided as an aqueous solution or a solid material.7. The ...

Подробнее
Номер записи: 43
14-11-2013 дата публикации

ORGAN PROTECTION, PRESERVATION AND RECOVERY

Номер: US20130302779A1
Автор: Dobson Geoffrey Phillip
Принадлежит: Hibernation Therapeutics Limited

This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ. 1. A method for reducing damage to a cell , tissue or organ following ischemia comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.2. A method according to claim 1 , wherein the composition further includes a delta-1-opioid receptor agonist.3. A method according to claim 2 , wherein the opioid is [D-Pen 2 claim 2 ,5]enkaphalin (DPDPE).4. A method according to claim 1 , wherein the adenosine receptor agonist is CCPA.5. A method for reducing damage to a cell claim 1 , tissue or organ following trauma comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.6. A method for reducing damage to a cell claim 1 , tissue or organ during ischemia or reperfusion:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.7. A method for reducing damage to a cell claim 1 , tissue or organ following ischemia comprising administering to the cell claim 1 , tissue or organ an effective amount of a composition including (i) a potassium channel opener or ...

Подробнее
Номер записи: 44
14-11-2013 дата публикации

Lid For Functionalized Microfluidic Platform And Method

Номер: US20130302842A1
Автор: David Beebe, David John Guckenberger, Erwin Berthier, Peter Cavner
Принадлежит: Individual

A microfluidic device and method is provided for handheld diagnostics and assays. A first substance is frozen in a cryopreservation fluid in a first well of a lid. The lid includes a first surface communicating with a first port of the first well and a second surface communicating with a second port of the first well. A porous membrane is affixed to the first surface so as to overlap the first port and a non-porous membrane is affixed to the second surface so as to overlap the second port. The first substance may be dialytically freed from the cryopreservation fluid at a user desired time. Thereafter, the lid may be moved from a first position wherein the lid is spaced from a base to a second position wherein the lid is adjacent the channel in the base such that the first substance communicates with the input of the channel.

Подробнее
Номер записи: 45
21-11-2013 дата публикации

Cooling system, especially for cryopreserving biological samples, comprising devices for use in case of an emergency

Номер: US20130305746A1
Автор: Guenter R. Fuhr, Heiko Zimmermann
Принадлежит: Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV

A cooling system ( 1 ), especially for cryopreserving biological samples ( 2 ), comprises a cooling chamber ( 100 ) delimited by a bottom area ( 110 ), side walls ( 120 ), and a top area ( 130 ), and a cooling device ( 200 ) for cooling the cooling chamber ( 100 ) using liquid nitrogen ( 220 ). At least one of the side walls ( 120 ) includes at least one predetermined wall element ( 125 ) which is a portion of at least one of the side walls and can be moved relative to the associated side wall ( 120 ) in such a way that a wall opening can be formed in said side wall ( 120 ). Methods for operating the cooling system ( 1 ) in case of an emergency are also described.

Подробнее
Номер записи: 46
21-11-2013 дата публикации

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

Номер: US20130309651A1
Автор: Lenz Richard, Moreno Juan, Vishwanath Ramakrishnan
Принадлежит: INGURAN, LLC

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1199-. (canceled)200. An improved method of producing an embryo using ART by reducing stress on the sperm cell during sperm processing , comprising:a. forming a sperm cell composition by adding one or more OSRs in the concentration range of 0.01 to 5 mg/ml to the sperm cell sample,b. holding the sperm cell composition for a period of time,c. processing the sperm cell composition, andd. using the sperm cell composition in assisted reproductive techniques (ART).201. The method of producing an embryo according to the method of claim 200 , wherein the ART is selected from the group consisting of: in vitro fertilization (IVF) claim 200 , artificial insemination (AI) claim 200 , intracytoplasmic sperm injection (ICSI) claim 200 , multiple ovulation and embryo transfer (MOET) claim 200 , and other embryo transfer techniques.202. The method of producing an embryo according to the method of claim 200 , wherein two or more OSRs are added at multiple processing steps to further enhance the integrity of the sperm and the embryo made with the ...

Подробнее
Номер записи: 47
12-12-2013 дата публикации

Cell-permeable variants of trehalose and methods for the protection of living cells

Номер: US20130331353A1
Автор: Margot G. Paulick
Принадлежит: Union College

A method for synthesizing variants of Tre; novel Tre variants; and a method for introducing Tre in sufficient concentration into the intracellular environment suitable to store treated mammalian cells, treat an aggregation disease, and protect treated cells from oxygen radicals are disclosed.

Подробнее
Номер записи: 48
26-12-2013 дата публикации

ARRESTING OBJECTS

Номер: US20130344473A1
Автор: DEUTSCH Mordechai, Moshkov Sergei, Shafran Yana
Принадлежит: Seng Enterprises Ltd.

A method and system for arresting objects in an array of chambers including, applying a solution to at least one chamber in an array of chambers, in a manner that does not connect two chambers, such that at least one object in the solution is arrested in said at least one chamber, the chambers having a volume of 0.5 microliters-3 microliters. 1. A method of arresting objects in an array of chambers comprising:applying a solution to at least one chamber in an array of chambers, in a manner that isolates said at least one chamber, such that at least one object in said solution is arrested in said at least one chamber; andsubstantially sealing said at least one chamber against escape of said objects by a liquid or a film or a gel cover for said at least one chamber, or by a plug.2. A method as in claim 1 , wherein said solution is applied to two chambers claim 1 , then said at least one chamber is isolated by reducing an amount of said solution in and/or around said chambers.3. A method as in claim 1 , wherein said solution is applied to said at least one chamber to a level no more than a height of walls of said at least one chamber.4. (canceled)5. A method as in claim 1 , wherein said cover comprises a fluid floating above said solution.6. A method as in claim 1 , wherein said cover repels water from said chambers.7. A method as in claim 1 , wherein said cover is a liquid claim 1 , and further comprising inserting said solution including said at least one object into said at least one chamber through said cover.89-. (canceled)10. A method as in claim 2 , wherein the amount of said solution is reduced by wicking.11. A method as in claim 1 , wherein said at least one object comprises a living cell or a molecule.12. A method as in claim 1 , wherein said at least one object comprises a sperm cell or a DNA molecule.1314-. (canceled)15. A method as in claim 1 , further including cryopreserving said arrested objects in said chambers.16. (canceled)17. A system according to ...

Подробнее
Номер записи: 49
26-12-2013 дата публикации

Method for Preserving Cells and Cell Cultures

Номер: US20130344596A1
Автор: Alexander N. Shumeev, Ilya Ilyin, James S. Jones, Natella I. Enukashvily, Semyon Kogan, Stanislav Kolchanov, William E. Grieshober, JR., Yana A. Filkina
Принадлежит: Advanced Preservations Technologies LLC

Provided is a method for reducing apoptosis in nucleated cells. The method entails holding nucleated cells in a container and adding a gas containing xenon to the container so that the pressure inside the container reaches between 0.5 to 4.0 Atm above ambient pressure; holding the container at between 0.5 to 4.0 Atm above ambient pressure for a period of time during which the temperature in the container is between 22° C. and 37° C.; lowering the temperature in the container to between 0.1° C. and 10° C. while maintaining the pressure of 0.5 to 4.0 Atm above ambient pressure and holding the container for a period of time; and reducing the pressure in the container to ambient pressure and increasing the temperature to 22° C.-37° C. By performing these steps, the cells undergo less apoptosis than a reference.

Подробнее
Номер записи: 50
09-01-2014 дата публикации

Method and apparatus for prevention of thermo-mechanical fracturing in vitrified tissue using rapid cooling and warming by persufflation

Номер: US20140011182A1
Автор: Stephen Van Sickle, Tanya Jones
Принадлежит: Arigos Biomedical Inc

A method and apparatus are disclosed for avoiding fracturing, e.g., thermo-mechanical fracturing, in vitrified biological systems via rapid cooling and/or warming persufflation techniques, by reducing the domain size of fracturing and by reducing thermal gradients. Also disclosed is a system adapted to rapidly cool and warm vitrifiable vascular biological tissue by persufflation, significantly reducing cryoprotectant toxicity from that of surface cooled tissue, in which the system is constructed and configured to use one or more of helium gas, hydrogen gas, neon gas, argon gas, krypton gas, xenon gas, oxygen gas, or various gaseous compounds. The system can be operated under pressure to increase the density and heat capacity of the gas relative to its density and heat capacity at atmospheric pressure and to cool the gas by one or more of mechanical action and by the phase change of a material such as a cryogenic gas or solid.

Подробнее
Номер записи: 51
16-01-2014 дата публикации

Perfusion apparatus with reduced pressure fluctuations, and bubble trap

Номер: US20140017658A1
Автор: Aaron R. FERBER, Christopher P. Steinman, Evan D. SHAPIRO, Jeffrey S. Louis, John Stark, Rick W. Walker, Rodney H. Monson, Ross Lockwood
Принадлежит: Lifeline Scientific Inc

An apparatus for separating gas bubbles that may be entrained in perfusate flow prevents such bubbles from continuing downstream and entering an organ or tissue. The apparatus may include a chamber having a top wall, a bottom wall and side walls. The chamber may include an inlet configured to allow at least one of gas and liquid to enter the chamber, an air opening configured to allow at least gas to exit the chamber and a first liquid opening configured to allow at least liquid to exit the chamber. The apparatus may function as an accumulator that reduces or eliminates pulsatility of the liquid flow and pressure. The apparatus may include a minimum volume of gas, initially or through the accumulation of gas, such that flow and pressure fluctuations in the liquid are dampened or eliminated. The apparatus may include a sampling port in a wall of the chamber.

Подробнее
Номер записи: 52
16-01-2014 дата публикации

Cannula

Номер: US20140017661A1
Автор: Brian Otts, Christopher P. Steinman, David Pettinato, James V. GUARRERA, Jason A. Belton, Karl H. Beitzel, Kirk C. Palmerton, Matthew Copithorne, Rick W. Walker
Принадлежит: Lifeline Scientific Inc

A cannula includes a first clamping surface on a closing portion of the cannula, a second clamping surface on a base of a cannula, a connecting structure that connects the closing portion and the base. The connecting structure may allow the closing portion to be rotated around the second clamping surface. The cannula may include a repeatably removable handle.

Подробнее
Номер записи: 53
16-01-2014 дата публикации

Organ transporter with tilt and/or shock sensing

Номер: US20140017663A1
Автор: Aaron R. FERBER, Christopher P. Steinman, Evan D. SHAPIRO, Joel C. HAGAN, John Stark, Rodney H. Monson
Принадлежит: Lifeline Scientific Inc

An apparatus for perfusing an organ or tissue includes a perfusion circuit configured to perfuse the organ or tissue; at least one shock and/or tilt detector such as an accelerometer; and a controller. The controller may be configured to control perfusion based upon a signal received from the accelerometer, which may include stopping and/or starting the perfusion based upon the signal. The controller may also or alternatively sense and/or record shocks experienced by the apparatus.

Подробнее
Номер записи: 54
16-01-2014 дата публикации

Organ transporter with oxygen generation

Номер: US20140017665A1
Автор: Aaron R. FERBER, Christopher P. Steinman, David Kravitz, Evan D. SHAPIRO, Rodney H. Monson, Ross Lockwood
Принадлежит: Lifeline Scientific Inc

An apparatus for perfusing an organ or tissue includes a perfusion circuit for perfusing the organ or tissue; an oxygenator for oxygenating perfusate that circulates through the perfusion circuit; and an oxygen supply device such as an oxygen concentrator or an oxygen generator configured to supply oxygen to the oxygenator. A method of perfusing an organ or tissue includes producing oxygen from a device such as an oxygen concentrator and an oxygen generator; supplying the produced oxygen, preferably as the oxygen is produced, to a perfusate to oxygenate the perfusate; and perfusing the organ or tissue with the oxygenated perfusate. The produced oxygen preferably has a concentration greater than the oxygen concentration in air.

Подробнее
Номер записи: 55
16-01-2014 дата публикации

System for collecting and preserving tissue cores

Номер: US20140017771A1
Автор: Brian C. Dougherty, Joseph L. Mark, Mick Trompen
Принадлежит: Nico Corp

A thermal system for preserving tissue is disclosed. The cooling system comprises a base member, a temperature control sleeve constructed of a thermally conductive material, and a selectively removable lid member. The base member defines a reservoir and receives the temperature control sleeve. The temperature control sleeve at least partially defines a tissue collector chamber that is configured to receive a tissue collector. The temperature control sleeve is in communication with the reservoir. The reservoir is configured to receive a cooling medium. A slit formed within the tissue collection chamber that is sized to receive a tubing connected to the tissue collector therethrough. The lid member is configured to be selectively attached to the base member, and permit access to a tube mount for the tissue collector when the lid is attached to the base member.

Подробнее
Номер записи: 56
23-01-2014 дата публикации

CRITICAL POINT DRYING SYSTEMS AND METHODS FOR IN SITU TISSUE PRESERVATION

Номер: US20140020220A1
Автор: TOUSIMIS Anastasios J.
Принадлежит:

Methods and systems for preserving tissues in situ using critical point drying are disclosed. Such methods and systems are particularly applicable to the preservation of a deceased body, such as a deceased person or animal, with or without removal of internal tissues or organs. A fixative can be perfused through the vascular system of the body while blood is removed from the body. The exterior of the body can also be immersed in a bath of fixative. The fixative in the vascular system and the bath can be replaced by subsequent washes of buffer, de-ionized water, and/or alcohol. The alcohol-infused and fixated body can be disposed in a pressure chamber and subjected to a critical point drying process using carbon dioxide. After the critical point drying process, the body is in a preserved state. 123-. (canceled)24. A system for preservation of a body or an organ thereof , the system comprising:a pressure chamber having at least one fluid inlet and a vascular inlet line, the vascular inlet line being constructed to connect to the vascular system of the body or the organ, the pressure chamber being sized and shaped so as to allow the body or the organ to be enclosed therein;a flow module configured to supply liquid carbon dioxide to the pressure chamber through the at least one fluid inlet and to the vascular system through the vascular inlet line;a temperature module configured to control the temperature of the pressure chamber; anda system controller configured to control the flow module to fill the pressure chamber and the vascular system with liquid carbon dioxide and to control the temperature module to heat the liquid carbon dioxide in the chamber and the vascular system above the carbon dioxide critical point temperature and pressure,wherein the pressure chamber is constructed to withstand a temperature and pressure of at least said carbon dioxide critical point temperature and pressure.25. The system of claim 24 , wherein the vascular inlet line is constructed ...

Подробнее
Номер записи: 57
30-01-2014 дата публикации

METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANS

Номер: US20140030231A1
Автор: Berendsen Timothy Antonie, Bieganski Robert Marius, IZAMIS Maria-Louisa, Perk Sinem, Toner Mehmet, Usta Osman Berk, Uygun Basak Elif, Uygun Mustafa Korkut, Yarmush Martin L.
Принадлежит: The General Hospital Corporation

The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage. 198-. (canceled)100. The method of claim 99 , wherein determining a measure of viability comprises comparing a measured energy parameter to a threshold representative of a transplantability threshold of an organ and/or a threshold representative of a cell harvesting threshold of an organ.101. The method of claim 99 , further comprising storing the organ prior to assessing its viability.102. The method of claim 99 , further comprising implanting the organ in a subject.103. The method of claim 99 , further comprising harvesting the cells of the organ.104. The method of claim 99 , wherein measuring for at least one energy parameter comprises assaying for the level of ATP in the organ claim 99 , measuring cellular energy status claim 99 , measuring the cellular energy status during normothermic perfusion of the organ claim 99 , measuring the level of a plurality of metabolites claim 99 , measuring the oxygen consumption by the organ claim 99 , measuring the level of the gluconeogenesis of the ...

Подробнее
Номер записи: 58
20-02-2014 дата публикации

HEMATOLOGY CONTROL COMPOSITIONS WITH EXTENDED STABILITY

Номер: US20140051063A1
Автор: Bagiotti-Sheldon Cristina, Chin Bruce, De Dibyendu, Parra-Diaz Dennisse
Принадлежит: Beckman Coulter, Inc.

The present specification provides hematology control compositions having particular utility with a red blood cell component for devices using electronic and optical means for blood determinations, and methods for using the compositions. 114-. (canceled)15. A hematology control composition comprising a red blood cell component and an isotonic suspension medium including a serum albumin component and a cholesterol component , wherein the composition has a free fatty acid concentration of less than about 4 mmol/liter; and wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a stable shelf life.16. The composition of claim 15 , wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a shelf life of the composition of at least ninety-five days.17. The composition of claim 15 , wherein the shelf life of the composition is represented by a stabilization in mean cell volume claim 15 , a stabilization in red blood cell distribution width claim 15 , or both.18. The composition of claim 15 , wherein the red blood cell component is present in an amount sufficient to be measurable with an automated hematology instrument.19. The composition of claim 15 , wherein the serum albumin component is present at a concentration of from about 30 grams/liter to about 50 grams/liter.20. The composition of claim 15 , wherein the serum albumin component comprises a ratio of serum albumin monomer to serum albumin dimer lower than about 5:1.21. The composition of claim 15 , wherein the cholesterol component is present at a concentration of from about 400 mg/liter to about 1200 mg/liter.22. The composition of claim 15 , further comprising a nonionic surfactant component.23. The composition of claim 22 , wherein the nonionic surfactant component comprises a poloxamer.24. The composition of claim 15 , which further comprises a white blood cell component.25. The composition of claim 24 , ...

Подробнее
Номер записи: 59
20-03-2014 дата публикации

Graft or tissue rinsing solution and method for rinsing said graft or tissue before revascularization

Номер: US20140080111A1
Автор: George-Antoine Lopez, Marcos Juan Net Abraham, Silvina Ramella Virieux
Принадлежит: Groupe IGL

Extracellular organ or tissue rinsing solution, comprising calcium, PEG with a molecular weight of 35 000 at a concentration of at least 4 g/l, and potassium at a concentration of greater than or equal to 1, but less than 10 mmol/l.

Подробнее
Номер записи: 60
27-03-2014 дата публикации

Red blood cell products and the storage of red blood cells in non-pvc containers

Номер: US20140086892A1
Автор: Craig L. Sandford, Katherine Radwanski, Kyungyoon Min
Принадлежит: Fenwal Inc

Red blood cell products are disclosed. The product includes a container made from a non-PVC, substantially plasticizer-free material. The product includes a RBC concentrate and a hypotonic solution for storing the RBCs.

Подробнее
Номер записи: 61
27-03-2014 дата публикации

Organ Transplant Solutions and Methods for Transplanting Organs

Номер: US20140087357A1
Автор: DEVARAJAN Prasad, Kohl Jorg
Принадлежит: CHILDREN'S HOSPITAL MEDICAL CENTER

A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated. 120.-. (canceled)21. A method of preservation , storage and reperfusion of an organ intended for implantation , said method comprising perfusing said organ with a solution comprising:(a) a balanced isotonic solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount;(b) a safe and effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated; and(c) water.22. The method of preservation according to wherein the C5a mutein is present at from about 0.1 to about 10 μM/liter of the solution.24. A method of preservation of organs intended for implantation claim 21 , said method comprising perfusing the body of the dead organ donor claim 21 , prior to removal of the organs claim 21 , with a solution comprising:(a) a balanced isotonic solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount;(b) a safe and effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated; and(c) water.26. The method of preservation according to wherein the C5a mutein is present at from about 0.1 to about 10 μM/liter of the solution.27. The method of claim 21 , wherein claim 21 , in the mutein claim 21 , the amino acid residue at ...

Подробнее
Номер записи: 62
10-04-2014 дата публикации

Platelet Additive Solution Having a beta-Galactosidase Inhibitor

Номер: US20140099629A1
Автор: Hoffmeister Karin, Liu Qiyong Peter, Sackstein Robert
Принадлежит:

The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof. 1. A platelet additive solution (PAS) , comprising:a. an amount of one or more β-galactosidase inhibitors and an amount of one or more sialidase inhibitors, and optionally an amount of one or more glycan-modifying agents; andb. one or more of PAS components that includes a salt, a citrate source, a carbon source, or any combination thereof.2. The PAS of claim 1 , wherein the PAS is maintained at a pH ranging between about 6.4 and about 7.6.3. The PAS of claim 1 , further including a phosphate source.4. The PAS of claim 2 , wherein the phosphate source is selected from the group consisting of sodium monophosphate claim 2 , sodium diphosphate claim 2 , sodium triphosphate claim 2 , and a combination thereof.5. The PAS of claim 1 , wherein the one or more PAS components include a citrate source claim 1 , and wherein the citrate source is selected from the group consisting of monosodium citrate claim 1 , disodium citrate claim 1 , trisodium citrate claim 1 , citric acid claim 1 , and a combination thereof.6. The PAS of claim 1 , wherein the one or more PAS components include a carbon source claim 1 , and wherein the carbon source is selected from the group consisting of acetate claim 1 , glucose claim 1 , and sucrose.7. The PAS of claim 6 , wherein the one or more PAS components include an acetate source claim 6 , and wherein the acetate source is selected from the group consisting of sodium acetate claim 6 , potassium acetate claim 6 , magnesium acetate claim 6 , and a combination thereof.8. The PAS of claim 1 , wherein the one or more PAS components include a salt claim 1 , and wherein the salt is selected from the ...

Подробнее
Номер записи: 63
03-01-2019 дата публикации

CRYOPRESERVATION OF VIABLE HUMAN SKIN SUBSTITUTES

Номер: US20190000071A1
Автор: Allen-Hoffmann B. Lynn, Comer Allen R., Gratz Kenneth R., Pirnstill John C.
Принадлежит:

The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for cryopreserving viable skin substitutes. 1. A method of cryopreserving an organotypically cultured skin equivalent to maintain viable tissue comprising:treating an organotypically cultured skin equivalent in a cryoprotectant solution in a single step;packaging said organotypically cultured skin equivalent to provide a packaged skin equivalent; andfreezing said packaged organotypically cultured skin equivalent to provide a cryopreserved skin equivalent.2. The method of claim 1 , wherein said cryoprotectant is provided in a solution comprising about 21% to 70% of said solution by volume.3. The method of claim 1 , wherein said cryoprotectant is glycerol.4. The method of claim 1 , wherein said freezing further comprises freezing said organotypically cultured skin equivalent in the absence of substantial excess cryoprotectant.5. The method of claim 1 , wherein said freezing further comprises freezing at about −80 C.6. The method of claim 1 , wherein said freezing further comprises direct exposure to temperatures ranging from about −50 C to −100 C.7. The method of claim 1 , wherein said packaging further comprises enclosing said cryopreserved skin equivalent in a sterile bag and enclosing said sterile bag in a second bag.8. The method of claim 1 , wherein said organotypically cultured skin equivalents comprise NIKS cells.9. The method of claim 8 , wherein said NIKS cells comprise an exogenous nucleic acid sequence encoding an exogenous polypeptide.10. The method of claim 1 , wherein said skin equivalent retains viability after thawing.11. The method of claim 10 , wherein said cryopreserved skin equivalent has an Aof at least 50% of a reference skin equivalent as determined by an MTT assay.12. The method of claim 1 , further comprising thawing said ...

Подробнее
Номер записи: 64
07-01-2016 дата публикации

Packaging assembly for storing tissue and cellular material

Номер: US20160000062A1
Автор: Austin JOHNSON, Roberto Bracone, Silvia Chen
Принадлежит: LifeNet Health

The invention is an improved packaging assembly for storing, distributing, treating, mixing, and dispensing tissue and/or cellular material and/or implantable material. The packaging assembly may include pouches, tubes, and a bag made of a sealable, flexible polymeric material that is open at one end and a needle-free swabable connector attached to the pouch at the other end and acting as a port to allow for the introduction or discharge of biological solutions, rinsing solution, and/or preservation solutions into the packaging assembly. The designed thickness of the wall of the packaging assembly facilitates efficient heat/cold transfer, which is useful for successful controlled rate freezing, quick thawing, and resuscitation of viable cells or tissue. The invention is also useful for combining additional biological fluids with the cellular material or tissue, and for efficient mixing of the biological fluids with the tissue and/or cellular material in the assembly.

Подробнее
Номер записи: 65
07-01-2016 дата публикации

Composition and method for preserving, transporting and storing living biological materials

Номер: US20160000063A1
Автор: Conradus Ghosal Gho
Принадлежит: Individual

Compositions and methods for preserving, transporting and/or storing natural and bioengineered living biological materials represent significant improvements over traditional compositions and methods for preservation, transport and/or storage of biological material by the virtue of their ability to significantly prevent and minimize loss of functional and physical (cell, tissue, and/or organ) integrity to occur in the biological material being preserved, transported and/or stored, particularly at temperatures above freezing point. The compositions and methods are also highly suitable for use in cosmetic procedures, in particular in transplantation of biological materials, especially for transplantation of autologous or allogeneic biological materials.

Подробнее
Номер записи: 66
07-01-2016 дата публикации

Platelet Storage and Reduced Bacterial Proliferation in Platelet Products Using a Sialidase Inhibitor

Номер: US20160000064A1
Автор: Hoffmeister Karin, Liu Qiyong Peter, Sackstein Robert
Принадлежит:

The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment. 1. A method for reducing sialidase activity and inhibiting proliferation of one or more bacteria in a platelet product preparation from one or more donors , wherein the method comprises the step of:a) adding the platelet product preparation to an amount of a sialidase inhibitor, adding an amount of a sialidase inhibitor to the platelet product preparation, or both, to thereby obtain a sialidase inhibitor-treated platelet product preparation;wherein a sialidase activity in the sialidase inhibitor-treated platelet product preparation is less than a sialidase activity in a platelet product preparation not subjected to step “a)”, proliferation of one or more bacteria in the sialidase inhibitor-treated platelet product preparation is less than a proliferation of said one or more bacteria in a platelet product preparation not subjected to step “a)”, and wherein the sialidase inhibitor inhibits an endogenous sialidase released by a platelet of the platelet product preparation.2. The method of claim 1 , wherein the one or more bacteria comprise bacteria found in platelet product preparations.3Aspergillus, BacillusBacteroides eggerthii, Candida albicans, CitrobacterClostridium perfringens, CorynebacteriumDiphtheroid, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter cloacae, Enterococcus avium, Enterococcus faecalis, Escherichia coli, FusobacteriumGranulicatella adiacens, ...

Подробнее
Номер записи: 67
07-01-2016 дата публикации

Cryopreservation of cells and subcellular fractions

Номер: US20160000065A1
Автор: Maciej Czerwinski
Принадлежит: XENOTECH LLC

The invention provides cryopreserved compositions of cells, wherein the compositions are advantageously in the form of self-sustaining bodies that can be individually handled and combined independently of a container, allowing for easy customization of the eventual pooled preparation. The invention also provides pre-pooled stacks of the self-sustaining cryopreserved compositions for eventual thawing to produce pooled preparations of cells. A mold and methods for forming the self-sustaining bodies are also provided. The invention is also concerned with methods of forming pooled preparations of cells using single-cryopreserved compositions of cells.

Подробнее
Номер записи: 68
04-01-2018 дата публикации

Platelet Protection Solution Having Beta-Galactosidase and Sialidase Inhibitors

Номер: US20180000066A1
Автор: Hoffmeister Karin, Liu Qiyong Peter, Sackstein Robert
Принадлежит:

The present invention relates to a platelet protection solution (PPS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof. 1. A platelet protection solution (PPS) , comprising:a. an amount of one or more β-galactosidase inhibitors and an amount of one or more sialidase inhibitors, and optionally an amount of one or more glycan-modifying agents;b. PPS components in a form of salt, consisting essentially of:a sodium source in an amount ranging between about 100 mM and about 300 mM;a chloride source in an amount ranging between about 40 mM and about 110 mM;an acetate source in an amount ranging between about 10 mM and about 50 mM;a phosphate source in an amount ranging between about 5 mM and about 50 mM;a potassium source in an amount ranging between about 0.5 mM and about 10 mM; anda magnesium source in an amount ranging between about 0.5 mM and about 5.0 mM.2. The PPS of claim 1 , further comprising at least one of the group consisting of:a. a calcium source in an amount ranging between about 0.1 mM and about 2.5 mM;b. a glucose source in an amount ranging between about 0.1 mM and about 30 mM;c. a citrate source in an amount ranging between about 2 mM and about 20 mM; andd. a combination thereof.3. The PPS of claim 1 , wherein the chloride source is present in the amount ranging between about 90 mM and about 110 mM;4. The PPS of claim 1 , wherein the PPS is maintained at a pH ranging between about 6.4 and about 7.6.5. The PPS of claim 1 , wherein the phosphate source is selected from the group consisting of sodium monophosphate claim 1 , sodium diphosphate claim 1 , sodium triphosphate claim 1 , and a combination thereof.6. The PPS of claim 2 , wherein the citrate source is selected from the group consisting of monosodium citrate ...

Подробнее
Номер записи: 69
05-01-2017 дата публикации

DEVICES AND METHODS TO IMPROVE AND ASSESS VIABILITY OF HUMAN LIVERS

Номер: US20170000110A1
Автор: BRUINSMA Bote G., IZAMIS Maria-Louisa, KORKUT Uygun
Принадлежит: The General Hospital Corporation

The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ. 1. An organ perfusion system operating at room temperature , the system comprisinga first container configured to encase an organ removed from a subject and store a perfusion fluid, whereby the organ is at least partially immersed in the perfusion fluid;a fluidic circuit system having a first end connected to the perfusion fluid stored in the first container and a second end connected to the organ, the fluidic circuit system configured to draw the perfusion fluid through the first end and perfuse the organ with the perfusion fluid, and wherein the organ perfusion system does not comprise a temperature controller.2. The organ perfusion system of claim 1 , wherein the organ perfusion system does not comprise a cleaning device for cleaning the perfusion fluid.3. (canceled)4. The organ perfusion system of claim 1 , wherein the organ perfusion system is portable.5. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises a pressure sensor configured to measure the pressure of the perfusion fluid flowing towards the organ.6. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises a pump configured to control the pressure of the perfusion fluid as a function of the measurements of the pressure sensor.7. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises an oxygenator configured to increase oxygen level in the perfusion fluid flowing towards the organ.8. The organ perfusion system of claim ...

Подробнее
Номер записи: 70
07-01-2021 дата публикации

STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES

Номер: US20210000103A1
Автор: DIAZ Paul, Muller Rolf, RABAN Robyn, WHITNEY Scott
Принадлежит:

The present invention relates to the stabilization of one or more metabolically-active cell in a blood sample at ambient temperatures. In particular, formulations, compositions, articles of manufacture, kits and methods for substantially stable storage of one or more metabolically-active cell in a blood sample at ambient temperatures are provided. 1. A formulation for substantially stable storage of one or more metabolically-active cell in a blood sample at ambient temperatures , wherein the one or more cell remains metabolically-active after storage at room temperature for a period of at least three days.2. The formulation of claim 1 , wherein at least 80% of the substantially stored cells remain metabolically-active after storage at room temperature for a period of at least three days.3. The formulation of or claim 1 , wherein at least 80% of the cells remain metabolically-active at room temperature for a period of at least 18 days.4. The formulation of any one of - claim 1 , comprising:(i) a pH buffer;(ii) a chelating agent; and(iii) a peptide.5. The formulation of claim 4 , wherein the pH buffer is selected from the group consisting of 2-(N-morpholino)ethanesulfonic acid (MES) claim 4 , 3-(N-morpholino)propanesulfonic acid (MOPS) claim 4 , 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) claim 4 , and a combination thereof.6. The formulation of any one of - claim 4 , wherein the peptide is a di-peptide or a tri-peptide.7. The formulation of any one of - claim 4 , wherein the di-peptide sequence is Ala-Gln or Gly-Gly and the tri-peptide sequence is Gly-Gly-Gly.8. The formulation of any one of - claim 4 , wherein the chelating agent is EDTA.9. The formulation of any one of - claim 4 , wherein the one or more metabolically-active cell is selected from the group consisting of a leukocyte claim 4 , an erythrocyte claim 4 , a circulating tumor cell claim 4 , and a combination thereof.10. The formulation of any one of - claim 4 , comprising:(i) a pH buffer;(ii) a ...

Подробнее
Номер записи: 71
07-01-2016 дата публикации

Modulating Ischemic Injury

Номер: US20160000874A1
Автор: Banas Richard A., Rupp Randall G., Sing George L., Steed David L.
Принадлежит: STEMNION, INC.

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 120.-. (canceled)21. A method for modulating ischemic injury in an ischemic lung , the method comprising the step of administrating a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) to the ischemic lung such that the ischemic injury is modulated , wherein the ACCS is formulated for spray administration.22. The method of wherein the ACCS is further formulated for sustained-release claim 21 , targeted-release claim 21 , timed-release claim 21 , or extended-release.23. A method for reducing ischemic injury in an ischemic lung claim 21 , the method comprising the step of administrating a composition comprising ACCS to the ischemic lung such that the ischemic injury is reduced claim 21 , wherein the ACCS is formulated for spray administration.24. The method of wherein the ACCS is further formulated for sustained-release claim 23 , targeted-release claim 23 , timed-release claim 23 , or extended-release.25. A method for increasing the time to ischemic injury in a lung at risk for developing ischemic injury claim 23 , the method comprising the step of administrating a composition comprising ACCS to the ischemic lung such that the time to ischemic injury is increased claim 23 , wherein the ACCS is formulated for spray administration.26. The method of wherein the ACCS is further formulated for ...

Подробнее
Номер записи: 72
04-01-2018 дата публикации

Methods and Compositions for Preserving the Viability of Photoreceptor Cells

Номер: US20180000930A1
Автор: Miller Joan, Zacks David N.
Принадлежит:

Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment. 1. A method of preserving the viability of photoreceptor cells disposed within a retina of a mammalian eye following retinal detachment , the method comprising:administering to a mammal having an eye in which a region of the retina has been detached an amount of an apoptosis inhibitor sufficient to preserve the viability of photoreceptor cells disposed within the region of the detached retina.2. The method of claim 1 , wherein the apoptosis inhibitor is administered to the mammal prior to reattachment of the region of detached retina.3. The method of claim 1 , wherein the apoptosis inhibitor is administered to the mammal after reattachment of the region of detached retina.4. The method of claim 1 , wherein the apoptosis inhibitor is administered locally or systemically.5. The method of claim 1 , wherein a plurality of apoptosis inhibitors are administered to the mammal.6. The method of claim 4 , wherein at least one apoptosis inhibitor is administered by intraocular claim 4 , intravitreal claim 4 , or transcleral administration.7. The method of claim 1 , wherein the apoptosis inhibitor reduces the number of photoreceptor cells in the region that die following retinal detachment relative to the number of photoreceptor cells that die in the absence of the apoptosis inhibitor.8. The method of claim 1 , wherein claim 1 , prior to administration of the apoptosis inhibitor claim 1 , the photoreceptor cells undergo apoptotic ...

Подробнее
Номер записи: 73
07-01-2016 дата публикации

METHODS OF UPSCALING MESENCHYMAL STROMAL CELL PRODUCTION, COMPOSITIONS AND KIT THEREOF

Номер: US20160002601A1
Автор: BALASUBRAMANIAN Sudha, Bhagwat Swaroop, Damodaran Devi, Kokundkar Udaykumar, Majumdar Anish Sen, Mruthynjaya Ashwin Kunigal, Raj Swathi Sundar, Ramadasse Balamurugan, THEJ Charan
Принадлежит:

The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss/cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C. 1. A process for culturing of mesenchymal stromal cells , said process comprising act of:a) allowing the mesenchymal stromal cells cultured till a first predetermined passage, to expand to a second predetermined passage in presence of culture media comprising basic fibroblast growth factor (bFGF);wherein said expansion is carried out by contacting the cells with said culture media when said cells achieve at least one pre-determined confluency; and wherein the process increases number of the cells at the end of the second predetermined passage by 2000 folds when compared to number of the cells at the first predetermined passage.2. The process as claimed in claim 1 , wherein the increase in the number of cells occurs in a maximum period of 21 days.3. The ...

Подробнее
Номер записи: 74
20-01-2022 дата публикации

Method and apparatus for freezing of biological products

Номер: US20220015354A1
Автор: Brent Owens, Brian Taylor, James Groom, Robert Woolley, Sean Cameron
Принадлежит: Vitrafy Life Sciences Pty Ltd

An apparatus for preserving biological products comprising an inner housing arranged within an outer insulated housing, wherein walls of the inner housing define a compartment for receiving biological products, said walls comprising an inlet wall for inflow of a heat exchange fluid into the compartment, an opposed outlet wall for outflow of a heat exchange fluid out of the compartment, side walls and a base, the side walls and base adjoining the inlet wall to the outlet wall, wherein the inlet wall and outlet wall each include a series of apertures to accommodate a continuous heat exchange fluid flow through the apparatus such that, in operation, biological products received in the compartment of the inner housing are immersed in the heat exchange fluid to exchange heat with the heat exchange fluid.

Подробнее
Номер записи: 75
20-01-2022 дата публикации

Container and cap assembly for cryogenic storage

Номер: US20220016622A1
Автор: Benjamin HUNT, Chase Bryan Jackson, Eric R. James
Принадлежит: Sanaria Inc, SIO2 Medical Products Inc

Disclosed are container and cap assemblies for cryogenic storage of materials at temperatures below negative 150° C. The container and cap assemblies disclosed maintain container closure integrity and fluid-tightness at ambient and cryogenic temperatures, optionally to preserve biologically active substances stored therein.

Подробнее
Номер записи: 76
14-01-2021 дата публикации

COMPOSITIONS AND METHODS FOR PRESERVING ORGAN TRANSPLANTS

Номер: US20210007347A1
Автор: GHATNEKAR Gautam S.
Принадлежит:

The present disclosure provides compositions and methods for preserving organs and tissues for transplantation, and for preventing cellular injury in organs or in subjects. 1. A method of preserving an organ or tissue for organ transplantation comprising contacting the organ with a solution comprising an isolated polypeptide comprising the carboxy-terminal amino acid sequence of an alpha connexin , or a conservative variant thereof.2. The method of claim 1 , wherein the organ is selected from the group consisting of heart claim 1 , kidneys claim 1 , liver claim 1 , lungs claim 1 , pancreas claim 1 , intestine claim 1 , and thymus.3. The method of claim 1 , wherein the polypeptide inhibits cellular injury in the organ or tissue.4. The method of claim 1 , wherein the method reverses cellular injury in the organ or tissue.5. The method of claim 1 , wherein the method rescues a marginal organ or tissue for transplantation claim 1 , wherein the marginal organ or tissue would not otherwise be suitable for transplantation.6. The method of claim 1 , wherein the polypeptidea. promotes cell-cell communication in the organ,b. stabilizes gap junctions in cells of the organ,c. stabilizes tight junctions in cells of the organ,d. inhibits or mitigates hemichannel activity in cells of the organ,e. inhibits apoptosis in cells of the organ,f. inhibits mitochondrial oxidant production in cells of the organ,g. promotes the integrity of endothelial cells of the organ,h. promotes barrier function of endothelial cells of the organ, and/ori. inhibits pro-inflammatory cytokine release from cells in the organ.7. The method of claim 6 , wherein the polypeptide inhibits pro-inflammatory cytokine release from cells in the organ claim 6 , and wherein the pro-inflammatory cytokine is IL-8.8. The method of claim 3 , wherein the cellular injury is caused by cold preservation induced damage.9. The method of claim 3 , wherein the cellular injury is caused by hypoxia.10. The method of claim 3 , ...

Подробнее
Номер записи: 77
14-01-2021 дата публикации

Stabilization of whole blood samples

Номер: US20210007348A1
Автор: Keith Wong, Mehmet Toner, Rebecca SANDLIN, Shannon Stott, Shannon Tessier
Принадлежит: General Hospital Corp

Methods for stabilizing blood samples, e.g., clinical blood samples, for storage or transportation before use.

Подробнее
Номер записи: 78
14-01-2021 дата публикации

Cryopreserving processes

Номер: US20210007349A1
Автор: Christopher Stubbs, Matthew Gibson, Trisha BAILEY
Принадлежит: University of Warwick

The present invention relates to processes for producing compositions for the cryopreservation of biological materials, e.g. cells and proteins. The compositions comprise a polyampholyte polymer. The invention also provides certain cryopreserving compositions comprising the polyampholyte polymer.

Подробнее
Номер записи: 79
11-01-2018 дата публикации

Freezing bag container

Номер: US20180007890A1
Автор: Masaki MATSUMURA
Принадлежит: Terumo Corp

A container for containing a freezing bag filled with biological tissue and for cooling and warming the freezing bag. The container includes a main body possessing an inner surface, a first side surface and a second side surface positioned opposite the first side surface. The main body is substantially rectangular parallelepiped shaped. The container includes at least one opening in at least one of the first side surface and the second side surface of the container, and at least two ridges spaced apart from one another on the inner surface of the container to create an air gap between the spaced apart ridges, the inner surface of the container and the outer surface of the freezing bag.

Подробнее
Номер записи: 80
10-01-2019 дата публикации

Automatic devices configured to perform a cryoprocedure on at least one biological sample carried by one or more carriers

Номер: US20190008142A1
Автор: Amir Arav
Принадлежит: FertileSafe Ltd

Automatic devices configured to perform a cryoprocedure on at least one biological sample carried by one or more carriers. The device includes a carrier holder, a container holder, a carrier driver and a container driver. The carrier holder holds the one or more carriers in an upright orientation while holding the at least one biological sample. The container holder holds two or more containers each in a predetermined location on the container holder. The carrier driver translates the carrier holder and the container driver translates the predetermined locations so as to position one of them in a position accessible to the carrier holder, so as to enable the carrier driver to submerge an active portion of each one or more carriers held by the carrier holder in a predetermined vertical depth in the position accessible to the carrier holder.

Подробнее
Номер записи: 81
14-01-2021 дата публикации

Carrier for freezing, storing, transporting, and thawing biological products storage bags

Номер: US20210007932A1
Автор: Joseph T. Alford, Lauren Myrick
Принадлежит: WL Gore and Associates Inc

A carrier for a storage bag is disclosed. The carrier includes a base and a lid that define an interior region in a closed configuration. The base and lid are configured to retain the storage bag and tubes of the storage bag within the interior region in the closed configuration. A distance between the base and lid in the closed configuration is adaptable between a contacting position and a floating position to allow for maximum contact of the storage bag with the base and the lid.

Подробнее
Номер записи: 82
27-01-2022 дата публикации

EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES

Номер: US20220022447A1
Автор: BIGLARNIA Alireza, JENSEN WAERN Marianne, Nilsson Bo, NILSSON EKDAHL Kristina, Teramura Yuji
Принадлежит:

An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammation and reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient. 116.-. (canceled)17. An ex vivo method of treating an organ or a part of the organ , the method comprising:ex vivo infusing a solution comprising poly(ethylene glycol)-phospholipid (PEG-phospholipid) molecules into a vascular system of the organ or the part of the organ; andex vivo incubating the solution comprising PEG-phospholipid molecules in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules.18. The method according to claim 17 , further comprising:ex vivo infusing an organ preservation solution into the vascular system to flush away non-bound PEG-phospholipid molecules from the vascular system.19. The method according to claim 17 , further comprising:ex vivo infusing an organ preservation solution into the vascular system prior to ex vivo infusing the solution comprising PEG-phospholipid molecules into the vascular system.20. The method according to claim 17 , wherein ex vivo infusing the solution comprises:ex vivo clamping one of an artery and a vein of the vascular system;ex vivo infusing the solution comprising PEG- ...

Подробнее
Номер записи: 83
11-01-2018 дата публикации

PATHOGEN-INACTIVATED RED BLOOD CELL COMPOSITIONS

Номер: US20180008639A1
Автор: ERICKSON Anna, MUFTI Naheed, NORTH Anne
Принадлежит:

The present invention provides pathogen-inactivated red blood cell compositions. 1116-. (canceled)117. A composition comprising red blood cells produced by a method of reducing dehydration in a red blood cell composition wherein the composition is a mixture comprising (a) a quencher capable of reacting with a pathogen-inactivating compound , (b) about 0.5 to 1.5 equivalents of base , wherein an equivalent means a molar amount that is equivalent to the molar amount of quencher in the mixture , (c) red blood cells , and (d) a treatment solution or diluent solution; wherein the treatment solution or diluent solution comprises one or more of dextrose , adenine , mannitol , citrate , and citric acid; and wherein the red blood cell composition comprises between about 40 mM and 100 mM chloride ion; wherein the method of reducing dehydration in the red blood cell composition comprises replacing the solution in the mixture with a final additive solution , such that the concentration of the quencher in the mixture is decreased to less than about 10 mM; wherein the level of dehydration of the red blood cell composition is decreased relative to the level of dehydration of a red blood cell composition comprising (a) , (c) , (d) , and 2.0 or greater equivalents of base and in which the solution in the mixture has not been replaced with a final additive solution.118. The composition of claim 117 , wherein the quencher comprises cysteine or a derivative of cysteine.119. The composition of claim 117 , wherein the quencher is glutathione or a pharmaceutically acceptable salt thereof.120. The composition of claim 117 , wherein the quencher is glutathione monosodium salt.121. The composition of claim 117 , wherein the concentration of the quencher is decreased to less than about 8 mM.122. The composition of claim 117 , wherein the concentration of the quencher is decreased to less than about 6 mM.123. The composition of claim 117 , wherein the red blood cells of the mixture after ...

Подробнее
Номер записи: 84
08-01-2015 дата публикации

COMPOSITION AND METHOD FOR ORGAN PRESERVATION

Номер: US20150010488A1
Автор: BERKA Nabil, DISSARD Dominique, GILOTIN Denis, GRAUGNARD Henri, JAY Jean-Charles
Принадлежит: OGF

The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for tissue and organ preservation and more particularly for the preservation of bodies and anatomical parts or for carrying out embalming procedures. 1. A method for organ preservation , comprising a step of contacting said organ with a composition comprising 2-bromo-2-nitropropane-1 ,3-diol , wherein said composition comprises from 0.1% to 0.5% by weight of 2-bromo-2-nitropropane-1 ,3-diol.2. The method of claim 1 , wherein said composition comprises 0.15% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol.3. The method of claim 1 , wherein the composition also comprises an anticoagulant.4. The method of claim 1 , wherein the composition also comprises a penetrating agent.5. The method of claim 1 , wherein the composition also comprises an antiseptic.6. The method of claim 6 , wherein the antiseptic is chosen between ethanol and methanol.7. The method of claim 6 , wherein the composition comprises from 2% to 45% by weight of antiseptic.8. The method of claim 1 , wherein the composition also comprises a coloring.9. A composition comprising 2-bromo-2-nitropropane-1 claim 1 ,3-diol claim 1 , an anticoagulant claim 1 , a penetrating agent claim 1 , an antiseptic and optionally a coloring claim 1 , said composition being characterized in that it comprises from 0.1% to 0.5% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol.10. A composition consisting of 2-bromo-2-nitropropane-1 claim 1 ,3-diol claim 1 , an anticoagulant claim 1 , a penetrating agent claim 1 , an antiseptic and optionally a coloring claim 1 , said composition being characterized in that it comprises from 0.1% to 0.5% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol. This application is a divisional application of U.S. patent application Ser. No. 12/922,264, having a filing date of Dec. 21, 2010, which is a National Stage Application of PCT/FR2009/050399, filed Mar. 11, 2009, all of said ...

Подробнее
Номер записи: 85
08-01-2015 дата публикации

Therapeutic placental compositions, methods of making and methods of use

Номер: US20150010506A1
Автор: Alla Danilkovitch, Amy Elizabeth Johnson, Dana Yoo, Gabriele Putz TODD, Jaime Zerhusen, Samson Tom, Timothy Jansen
Принадлежит: Osiris Therapeutics Inc

This invention provides a therapeutic placental composition comprising placental cells and other placental components derived from placental tissue. A cryopreserved placental composition is also provided. The placental compositions can be used to stimulate and promote angiogenesis, reduce inflammation, and to reduce scar formation, among others. The placental tissue can optionally be an amnion, chorion, a trophoblast-depleted chorion, umbilical cord, Wharton's jelly, placental cotyledon, and/or maternal decidua. The placental composition of the present invention is useful in treating a patient with a tissue injury (e.g., wound or burn) by applying the placental composition to the injury or in close proximity. Placental compositions may also be used to promote or increase regeneration of tissue. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Подробнее
Номер записи: 86
14-01-2021 дата публикации

Biological sheet fixing device

Номер: US20210008563A1
Автор: Shi Zhou
Принадлежит: BOE Technology Group Co Ltd

A biological sheet fixing device includes a carrying layer configured to carry a biological sheet, a carrying portion configured to carry the carrying layer, and a fixing portion configured to fix the carrying layer to the carrying portion.

Подробнее
Номер записи: 87
08-01-2015 дата публикации

Additive solution for blood preservation

Номер: US20150010897A1
Автор: Mark W. Bitensky, Tatsuro Yoshida
Принадлежит: Boston University

A method for the storage of red blood cells provides for mixing an additive solution with packed red blood cells to create a suspension of red blood cells. The method further provides for reducing the oxygen in the suspension of red blood cells; and storing the suspension of red blood cells under oxygen-depleted storage.

Подробнее
Номер записи: 88
14-01-2016 дата публикации

METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1

Номер: US20160010061A1
Автор: Taylor-Fishwick David
Принадлежит:

Methods of preserving and/or protecting pancreatic beta cells by inhibiting NOX-1. In a further aspect, NOX-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes. NOX-1 inhibitors are also disclosed; The method can be used to preserve beta cell/islet survival in vitro, or in vivo in cells exposed to stressful stimuli including but not limited to inflammation, inflammatory cytokines, high glucose, or elevated free fatty acids. 1. A method to preserve and/or protect beta cell function comprising contacting a population or preparation of pancreatic cells , beta cells and/or islets with an inhibitor of NADPH oxidase-1 (NOX-1).2. The method of wherein the NOX-1 inhibitor is a phenothiazine or a pyrazolopyridine dione compound.3. The method of wherein the NOX-1 inhibitor is 2-acetylphenothiazine.4. The method of wherein the NOX-1 inhibitor is Methyl-2-phenyl-5-(2-pyridinylmethyl)-1H-pyrazolo[4 claim 1 ,3-c]pyridine-3 claim 1 ,6(2H claim 1 ,5H)-dione or 5-Benzyl-4-methyl-2-phenyl-1H-pyrazolo[4 claim 1 ,3-c]pyridine-3 claim 1 ,6(2H claim 1 ,5H)-dione.5. The method of wherein the NOX-1 inhibitor is an siRNA for NOX-1.6. The method of wherein the pancreatic cells claim 1 , beta cells and/or islets have been exposed to stressful stimuli.7. The method of wherein the stressful stimuli is selected from the group consisting of inflammation claim 6 , inflammatory cytokines claim 6 , high glucose claim 6 , elevated free fatty acids and combinations thereof.8. The method of wherein the contacting step is in vitro.9. The method of wherein the contacting step is in vivo.10. The method of wherein the contacting step is ex vivo.11. A method of treating a subject for diabetes claim 1 , the method comprising administering a therapeutically effective amount of a NOX-1 inhibitor to the subject.12. The method of wherein the NOX-1 inhibitor is selected from the group consisting of 1-acetyl-4-methyl-2-phenyl-5-( ...

Подробнее
Номер записи: 89
11-01-2018 дата публикации

Transportable container, charger system, method and kit for generation of carbon dioxide snow block in-situ within the transportable container for preservation of items stored therewithin

Номер: US20180010839A1
Автор: Ranko BURSAC, Robert R Sever, YING Zhou
Принадлежит: Praxair Technology Inc

This invention relates to a novel kit, transportable apparatus and method for generating in-situ CO2 snow block within the apparatus. An item such as a biological sample can be stored and transported within the same apparatus that is employed for creating the CO2 snow block. The apparatus is capable of preserving the sample during transport. The invention also includes a specially designed CO2 snow charger system including a charger and meshed conduit. The charger system is operated in accordance with the methods of the present invention to create the in-situ CO2 snow block within a container that can be also used for transport.

Подробнее
Номер записи: 90
15-01-2015 дата публикации

COMPOSITION AND METHOD FOR TISSUE PRESERVATION AND EMBALMING

Номер: US20150013125A1
Автор: BERKA Nabil, DISSARD Dominique, GILOTIN Denis, GRAUGNARD Henri, JAY Jean-Charles
Принадлежит: OGF

The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for tissue preservation and more particularly for the preservation of bodies and anatomical parts or for carrying out embalming procedures. 1. An embalming method , comprising the step of injecting into the body to be embalmed a composition comprising 2-bromo-2-nitropropane-1 ,3-diol , wherein said composition comprises from 2% to 8% by weight of 2-bromo-2-nitropropane-1 ,3-diol and wherein the composition is injected by cavity injection.2. The embalming method of claim 1 , wherein said composition comprises from 2.5% to 5% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol.3. The embalming method of claim 1 , wherein said composition comprises 5% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol.4. The method of claim 1 , wherein the composition also comprises an anticoagulant.5. The method of claim 1 , wherein the composition also comprises a penetrating agent.6. The method of claim 1 , wherein the composition also comprises an antiseptic.7. The method of claim 6 , wherein the antiseptic is chosen between ethanol and methanol.8. The method of claim 6 , wherein the composition comprises from 2% to 45% by weight of antiseptic.9. The method of claim 1 , wherein the composition also comprises a coloring.10. A composition comprising 2-bromo-2-nitropropane-1 claim 1 ,3-diol and an antiseptic claim 1 , said composition being characterized in that it comprises from 2% to 8% by weight of 2-bromo-2-nitropropane-1 claim 1 ,3-diol.11. The composition of claim 10 , also comprising an anticoagulant claim 10 , a penetrating agent and optionally a coloring.12. A composition consisting of 2-bromo-2-nitropropane-1 claim 10 ,3-diol and an antiseptic claim 10 , and optionally a coloring claim 10 , said composition being characterized in that it comprises from 2% to 8% by weight of 2-bromo-2-nitropropan-1 claim 10 ,3-diol. This application is a divisional application of U.S. ...

Подробнее
Номер записи: 91
03-02-2022 дата публикации

CRYOPRESERVATIVE COMPOSITIONS AND METHODS

Номер: US20220030850A1
Автор: Hubel Allison, Pollock Kathryn Lindsay
Принадлежит:

This disclosure describes a cryopreservative composition and methods for storing cells. Generally, the cryopreservative composition includes a sugar component and a sugar alcohol component, and is effective for storing and recovering cells without requiring dimethyl sulfoxide (DMSO). 118.-. (canceled)19. A cryopreservative composition comprising:a sugar component;a total concentration of 2 M or less of sugar alcohol components; andan amino acid or peptide;wherein the cryopreservative composition is substantially free of dimethyl sulfoxide (DMSO).20. The cryopreservative composition of wherein the sugar component is provided at a concentration of 0.1 mM to 300 mM.21. The cryopreservative composition of wherein the sugar component comprises a disaccharide.22. The cryopreservative composition of wherein the sugar component comprises trehalose claim 19 , fructose claim 19 , sucrose or glucose.23. The cryopreservative composition of wherein the sugar alcohol components are provided at a total concentration of 0.1 M or greater.24. The cryopreservative composition of wherein the sugar alcohol components are provided at a total concentration of 0.1 M to 1.4 M.25. The cryopreservative composition of wherein the sugar alcohol components comprise glycerol claim 19 , arabitol claim 19 , sorbitol claim 19 , ethylene glycol claim 19 , inositol claim 19 , xylitol claim 19 , mannitol claim 19 , or a combination thereof.26. The cryopreservative composition of wherein the sugar alcohol components comprise glycerol at a concentration of 0.6 M to 1.4 M.27. The cryopreservative composition of wherein the amino acid or peptide is provided at a concentration of from 0.1 mM to 300 mM.28. The cryopreservative composition of wherein the amino acid or peptide comprises proline claim 27 , valine claim 27 , alanine claim 27 , creatine claim 27 , isoleucine claim 27 , histidine claim 27 , taurine claim 27 , ectoine claim 27 , betaine claim 27 , dimethylglycine claim 27 , ethylmethylglycine claim ...

Подробнее
Номер записи: 92
03-02-2022 дата публикации

MODULATING ISCHEMIC INJURY

Номер: US20220030851A1
Автор: Banas Richard A., Rupp Randall G., Sing George L., Steed David L.
Принадлежит:

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS).2. The method of wherein the ACCS is formulated for sustained-release claim 1 , targeted-release claim 1 , timed-release claim 1 , or extended-release.3. The method of wherein the tissue or organ is a donated tissue or organ intended for transplant.4. The method of wherein the tissue is selected from the group consisting of epithelial tissue claim 1 , connective tissue claim 1 , muscle tissue and nervous tissue.5. The method of wherein the organ is selected from the group consisting of heart claim 1 , blood vessel claim 1 , alimentary canal claim 1 , stomach claim 1 , liver claim 1 , pancreas claim 1 , spleen claim 1 , kidney claim 1 , lung claim 1 , trachea claim 1 , cornea claim 1 , lens claim 1 , eye claim 1 , bladder claim 1 , ureter claim 1 , urethra claim 1 , uterus claim 1 , ovary claim 1 , testis claim 1 , nerve claim 1 , skin claim 1 , tooth claim 1 , and skeletal muscle.6. A method for reducing ischemic injury in tissues or organs claim 1 , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising ACCS.7. The method of wherein the ...

Подробнее
Номер записи: 93
19-01-2017 дата публикации

METHOD OF PREPARING EMBRYOS FOR CRYOPRESERVATION

Номер: US20170013826A1
Автор: Burbank Fred H., Jones Michael L.
Принадлежит: Mariposa Biotechnology, Inc.

An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts. 1. A method of preparing embryos for cryopreservation , said method comprising:positioning one or more embryos in a container; andflowing a first solution comprising a cryoprotectant over the embryos by delivering the first solution into the container and removing the first solution from the container, for a first time period;while delivering the first solution into the container, initiating flow of a second solution comprising a dehydrating agent into the container;wherein the step of initiating flow of the second solution is initiated while some of the first solution is in the processing container, and accomplished to gradually increase the concentration of the dehydrating agent in the container.2. The method of claim 1 , wherein the concentration of the cryoprotectant in the first solution is increased from about 0.0 M to about 1.5 M during the first period.3. The method of claim 1 , wherein the concentration of the dehydrating components in the second solution is increased from about 0.0 M to about 0.3 M during a second time period following the first time period.4. The method of claim 2 , wherein the concentration of the dehydrating components in the second solution is increased from about 0.0 M to about 0.3 M during a second time period following the first time period.5. The method of claim 1 , further comprising the step of:prior to delivering the first solution comprising a cryoprotectant into the container, delivering a stabilizing solution into the container, and thereafter delivering the first solution, during the first time period, to gradually increase ...

Подробнее
Номер записи: 94
19-01-2017 дата публикации

METHOD OF PREPARING BLASTOCYSTS FOR CRYOPRESERVATION

Номер: US20170013827A1
Автор: Burbank Fred H., Jones Michael L.
Принадлежит: Mariposa Biotechnology, Inc.

An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts. 1. A method of preparing blastocysts for cryopreservation , said method comprising:positioning one or more blastocysts in a container; andflowing a first solution comprising a cryoprotectant over the blastocysts by delivering the first solution into the container and removing the first solution from the container, for a first time period;while delivering the first solution into the container, initiating flow of a second solution comprising a dehydrating agent into the container;wherein the step of initiating flow of the second solution is initiated while some of the first solution is in the processing container, and accomplished to gradually increase the concentration of the dehydrating agent in the container.2. The method of claim 1 , wherein the concentration of the cryoprotectant in the first solution is increased from about 0.0 M to about 1.5 M during the first period.3. The method of claim 1 , wherein the concentration of the dehydrating components in the second solution is increased from about 0.0 M to about 0.3 M during a second time period following the first time period.4. The method of claim 2 , wherein the concentration of the dehydrating components in the second solution is increased from about 0.0 M to about 0.3 M during a second time period following the first time period.5. The method of claim 1 , further comprising the step of:prior to delivering the first solution comprising a cryoprotectant into the container, delivering a stabilizing solution into the container, and thereafter delivering the first solution, during the first time period, to ...

Подробнее
Номер записи: 95
19-01-2017 дата публикации

USES OF OXYGENATED CHOLESTEROL SULFATES (OCS)

Номер: US20170014429A1
Автор: Brown James E., LIN WeiQi, REN Shunlin, Theeuwes Felix
Принадлежит:

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted). 1. A method of prophylactically treating or treating ischemia caused by surgery in a subject in need thereof , comprisingadministering to the subject an amount of 5-cholesten-3,25-diol, 3-sulfate (25HC3S) that is sufficient to prophylactically treat or treat ischemia.2. The method of claim 1 , wherein the ischemia comprises at least one member selected from cardiac ischemia claim 1 , brain ischemia claim 1 , bowel ischemia claim 1 , limb ischemia claim 1 , and cutaneous ischemia.3. The method of claim 1 , wherein the prophylactically treating or treating ischemia comprises reducing one or more of inflammation claim 1 , tissue necrosis claim 1 , organ necrosis claim 1 , risk of stroke claim 1 , and reperfusion injury in the subject.4. The method of claim 1 , wherein the surgery comprises at least one of cardiovascular surgery claim 1 , heart surgery claim 1 , and aneurysm surgery.5. The method of claim 1 , wherein the 25HC3S is administered for not more than seven days prior to the surgery.6. The method of claim 1 , wherein the 25HC3S is administered during the surgery.7. The method of claim 1 , wherein the 25HC3S is administered for not more than seven days after the surgery.8. The method of claim 1 , wherein the surgery is not liver surgery.9. The method of claim 1 , wherein the surgery is not a transplant surgery.11. The method of claim 10 , wherein the one or more organs comprises at least one member selected from the liver claim ...

Подробнее
Номер записи: 96
21-01-2016 дата публикации

Method for Preparing Adipose Tissue

Номер: US20160015024A1
Автор: David Thomas Harris
Принадлежит: AdiCyte Inc

This disclosure presents methodologies for processing, cryogenic storage, retrieval and preparation of a tissue for transplantation. As such, the methods provide a system by which tissue for transplantation can be reliably and safely processed and stored for an extended period of time until the tissue is desired to be used.

Подробнее
Номер записи: 97
21-01-2016 дата публикации

CRYOPRESERVATIVE COMPOSTIONS AND METHODS

Номер: US20160015025A1
Автор: BISCHOF John C., CHOI Jeunghwan, ETHERIDGE Michael L.
Принадлежит:

This disclosure describes compositions and methods related to cryoprotection of biomaterial. Generally, the cryoprotective composition includes a cryoprotective agent and magnetic nanoparticles effective for thawing a cryopreserved specimen comprising biomaterial with minimal biomaterial damage. In some embodiments, the composition is effective for thawing a cryopreserved specimen having a minimum dimension of 0.1 mm. Generally, the method includes obtaining a biomaterial cryopreserved with a cryoprotective composition as summarized above, then subjecting the cryopreserved biomaterial to electromagnetic energy of an intensity sufficient to excite the magnetic nanoparticles and thaw the biomaterial.

Подробнее
Номер записи: 98
18-01-2018 дата публикации

Method of introduction and removal of high concentrations of cryoprotectants by vascular perfusion

Номер: US20180014823A1
Автор: Gregory Michael FAHY
Принадлежит: 21St Century Medicine Inc

Surgical tools which are used to separate from one another a femoral cup and an acetabular ball in an implanted hip replacement prosthesis. At its distal end, elements of the surgical tool engage the femoral cup and the acetabular cup. When proximal handles of the tool are squeezed toward one another, the engagement elements move away from one another. Thus, a surgeon is able to separate the femoral cup and the acetabular ball from one another without pulling the acetabular cup away from the acetabulum or the femoral cup and/or femoral implant away from the femur, thereby accomplishing the separation without disrupting any bone ingrowth.

Подробнее
Номер записи: 99
17-01-2019 дата публикации

SYSTEMS, METHODS, COMPOSITIONS AND SOLUTIONS FOR PERFUSING AN ORGAN

Номер: US20190014774A1
Автор: HASSANEIN Waleed H., KHAYAL Tamer I., LEZBERG Paul
Принадлежит: TransMedics, Inc.

The invention, in various embodiments, provides systems, methods and solutions for perfusing an organ. 1. A perfusion system configured for maintaining an ex-vivo heart in a functioning state under physiological or near physiological conditions comprising:a first chamber containing a first solution;a second chamber containing a second solution;a mixing chamber;a first fluid line in fluid communication with the first chamber and the second chamber configured to carry the first solution and the second solution to the mixing chamber; a second fluid line in fluid communication with the mixing chamber configured to carry fluid from the mixing chamber to the ex vivo heart; and', 'a third fluid line in fluid communication with the ex vivo heart to carry fluid away from the ex vivo heart to the mixing chamber;, 'a perfusion circuit comprisingwherein the first solution and the second solution are combined in the mixing chamber prior to being carried to the perfusion circuit.2. The system of further comprising a priming solution configured to be added to the perfusion circuit.3. The system of wherein the first solution or the second solution comprise a third solution comprising components capable of being sterilized.4. The system of further comprising a Perfusion fluid in fluid communication with the ex vivo heart claim 2 , wherein the perfusion fluid comprises a blood product.5. The system of wherein the perfusion fluid comprises blood.6. The system of wherein the perfusion fluid comprises synthetic blood.7. The system of wherein at least one of the first solution claim 2 , the second solution claim 2 , and the priming solution are configured to be combined with a blood product.8. The system of wherein one of at least the first solution claim 2 , the second solution claim 2 , and the priming solution comprises one or more cardio stimulants.9. The system of wherein one of at least the first solution claim 2 , the second solution claim 2 , and the priming solution comprises ...

Подробнее
Номер записи: 100